https://trial.medpath.com/news/catheter-precision-divests-atherectomy-assets-for-15000-to-focus-on-electrophysiology-growth 2026-02-19T10:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-divests-atherectomy-assets-for-15000-to-focus-on-electrophysiology-growth 2026-02-19T10:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-raises-850-million-in-debut-bond-offering-to-finance-amicus-therapeutics-acquisition 2026-02-19T09:02:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-raises-850-million-in-debut-bond-offering-to-finance-amicus-therapeutics-acquisition 2026-02-19T09:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/eupraxia-pharmaceuticals-raises-55-million-to-advance-eosinophilic-esophagitis-treatment 2026-02-19T05:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eupraxia-pharmaceuticals-raises-55-million-to-advance-eosinophilic-esophagitis-treatment 2026-02-19T05:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/organigram-completes-eur107-3-million-acquisition-of-sanity-group-with-british-american-tobacco-investment 2026-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organigram-completes-eur107-3-million-acquisition-of-sanity-group-with-british-american-tobacco-investment 2026-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-acquires-faeth-therapeutics-for-200m-to-advance-pi3k-akt-mtor-pathway-inhibitor-piktor 2026-02-19T01:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-acquires-faeth-therapeutics-for-200m-to-advance-pi3k-akt-mtor-pathway-inhibitor-piktor 2026-02-19T01:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-therapeutics-launches-pivya-first-novel-uti-antibiotic-in-decades-for-us-market 2026-02-19T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-therapeutics-launches-pivya-first-novel-uti-antibiotic-in-decades-for-us-market 2026-02-19T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-s-del-desiran-shows-promise-for-myotonic-dystrophy-type-1-in-phase-1-2-marina-trial-published-in-nejm 2026-02-19T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-s-del-desiran-shows-promise-for-myotonic-dystrophy-type-1-in-phase-1-2-marina-trial-published-in-nejm 2026-02-19T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/cyanocapture-and-persist-ai-partner-to-build-world-s-first-robotic-gmp-facility-for-oral-protein-and-peptide-drugs 2026-02-19T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyanocapture-and-persist-ai-partner-to-build-world-s-first-robotic-gmp-facility-for-oral-protein-and-peptide-drugs 2026-02-19T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-launches-revolutionary-blood-collection-tubes-using-snake-venom-derived-technology-in-japan 2026-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-launches-revolutionary-blood-collection-tubes-using-snake-venom-derived-technology-in-japan 2026-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monkeypox-treatment-pipeline-expands-with-mrna-vaccines-and-novel-therapeutics-from-major-pharma-companies 2026-02-18T21:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monkeypox-treatment-pipeline-expands-with-mrna-vaccines-and-novel-therapeutics-from-major-pharma-companies 2026-02-18T21:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-reports-positive-phase-1a-results-for-novel-kv1-3-channel-blocker-zp9830-in-autoimmune-disease-development 2026-02-18T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-reports-positive-phase-1a-results-for-novel-kv1-3-channel-blocker-zp9830-in-autoimmune-disease-development 2026-02-18T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-in-38m-deal-for-gut-targeted-therapy 2026-02-18T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-in-38m-deal-for-gut-targeted-therapy 2026-02-18T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-vaccine-shows-durable-immune-responses-in-triple-negative-breast-cancer-trial 2026-02-18T21:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-mrna-vaccine-shows-durable-immune-responses-in-triple-negative-breast-cancer-trial 2026-02-18T21:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/sift-biosciences-raises-3-7m-to-develop-memory-t-cell-immunotherapy-platform-for-cold-tumors 2026-02-18T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sift-biosciences-raises-3-7m-to-develop-memory-t-cell-immunotherapy-platform-for-cold-tumors 2026-02-18T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-unveils-first-in-class-cd137-anchored-immunotherapy-ank-203-with-promising-preclinical-anti-tumor-activity 2026-02-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankyra-therapeutics-unveils-first-in-class-cd137-anchored-immunotherapy-ank-203-with-promising-preclinical-anti-tumor-activity 2026-02-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-biotech-starget-pharma-raises-18m-to-advance-ai-driven-radiopharmaceutical-cancer-therapies 2026-02-18T21:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-biotech-starget-pharma-raises-18m-to-advance-ai-driven-radiopharmaceutical-cancer-therapies 2026-02-18T21:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-pharmaceuticals-appoints-former-allergan-ceo-david-pyott-to-board-of-directors 2026-02-18T21:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarsus-pharmaceuticals-appoints-former-allergan-ceo-david-pyott-to-board-of-directors 2026-02-18T21:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/feinstein-institutes-scientists-transform-detrimental-immune-element-into-novel-sepsis-and-rheumatoid-arthritis-therapy 2026-02-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feinstein-institutes-scientists-transform-detrimental-immune-element-into-novel-sepsis-and-rheumatoid-arthritis-therapy 2026-02-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-completes-phase-0-trial-of-igf-antibody-xentuzumab-in-prostate-cancer-patients 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-completes-phase-0-trial-of-igf-antibody-xentuzumab-in-prostate-cancer-patients 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/korsana-biosciences-emerges-with-175m-to-develop-next-generation-alzheimer-s-antibody-therapy 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korsana-biosciences-emerges-with-175m-to-develop-next-generation-alzheimer-s-antibody-therapy 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/newbiologix-publishes-breakthrough-hek293-cell-line-data-showing-two-fold-improvement-in-gene-therapy-vector-production 2026-02-18T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newbiologix-publishes-breakthrough-hek293-cell-line-data-showing-two-fold-improvement-in-gene-therapy-vector-production 2026-02-18T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/rna-interference-therapy-market-expands-with-90-drugs-in-development-across-40-companies 2026-02-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-interference-therapy-market-expands-with-90-drugs-in-development-across-40-companies 2026-02-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/pluri-secures-china-patent-for-large-scale-immune-cell-manufacturing-platform 2026-02-18T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluri-secures-china-patent-for-large-scale-immune-cell-manufacturing-platform 2026-02-18T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/grunenthal-initiates-phase-i-trial-of-novel-nav-1-8-inhibitor-for-non-opioid-pain-management 2026-02-18T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grunenthal-initiates-phase-i-trial-of-novel-nav-1-8-inhibitor-for-non-opioid-pain-management 2026-02-18T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-breakthrough-enables-integration-of-serum-and-plasma-proteomic-data-for-enhanced-cancer-biomarker-research 2026-02-18T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-breakthrough-enables-integration-of-serum-and-plasma-proteomic-data-for-enhanced-cancer-biomarker-research 2026-02-18T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-fda-approval-for-pediatric-pah-treatment-while-launching-respiratory-device-in-india 2026-02-18T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-fda-approval-for-pediatric-pah-treatment-while-launching-respiratory-device-in-india 2026-02-18T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/unnatural-products-partners-with-novartis-in-1-7-billion-macrocyclic-peptide-deal-for-cardiovascular-therapeutics 2026-02-18T17:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unnatural-products-partners-with-novartis-in-1-7-billion-macrocyclic-peptide-deal-for-cardiovascular-therapeutics 2026-02-18T17:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-two-rapid-tests-for-critical-drug-resistant-pathogens 2026-02-18T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-two-rapid-tests-for-critical-drug-resistant-pathogens 2026-02-18T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-launches-clia-certified-laboratory-to-advance-precision-medicine-development 2026-02-18T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrivon-therapeutics-launches-clia-certified-laboratory-to-advance-precision-medicine-development 2026-02-18T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/rezon-bio-secures-fda-approval-for-commercial-biosimilar-manufacturing-at-warsaw-duchnice-facility 2026-02-18T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezon-bio-secures-fda-approval-for-commercial-biosimilar-manufacturing-at-warsaw-duchnice-facility 2026-02-18T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-national-cancer-clinical-trials-alliance-and-liquid-biopsy-foundation-to-address-growing-cancer-burden 2026-02-18T17:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-national-cancer-clinical-trials-alliance-and-liquid-biopsy-foundation-to-address-growing-cancer-burden 2026-02-18T17:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/xingimaging-selected-to-lead-imaging-operations-for-landmark-alzheimer-s-tau-platform-phase-ii-trial 2026-02-18T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xingimaging-selected-to-lead-imaging-operations-for-landmark-alzheimer-s-tau-platform-phase-ii-trial 2026-02-18T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/trellus-health-secures-six-month-extension-with-johnson-johnson-for-ibd-digital-platform 2026-02-18T12:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trellus-health-secures-six-month-extension-with-johnson-johnson-for-ibd-digital-platform 2026-02-18T12:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacelera-secures-eur6m-to-accelerate-quantum-ai-drug-discovery-platform-in-us-market 2026-02-18T12:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacelera-secures-eur6m-to-accelerate-quantum-ai-drug-discovery-platform-in-us-market 2026-02-18T12:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-drug-discovery-startup-peptris-secures-7-7m-series-a-to-advance-clinical-pipeline 2026-02-18T12:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-drug-discovery-startup-peptris-secures-7-7m-series-a-to-advance-clinical-pipeline 2026-02-18T12:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-achieve-14-million-fold-expansion-of-cancer-fighting-nk-cells-from-single-stem-cell 2026-02-18T05:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-achieve-14-million-fold-expansion-of-cancer-fighting-nk-cells-from-single-stem-cell 2026-02-18T05:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-s-pharmac-proposes-funding-for-two-chronic-lymphocytic-leukemia-combination-therapies 2026-02-18T01:04:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-s-pharmac-proposes-funding-for-two-chronic-lymphocytic-leukemia-combination-therapies 2026-02-18T01:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/watchmaker-genomics-licenses-crispr-cas9-technology-from-caribou-biosciences-for-novel-ngs-library-normalization 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/watchmaker-genomics-licenses-crispr-cas9-technology-from-caribou-biosciences-for-novel-ngs-library-normalization 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/seek-labs-receives-2-million-usda-grant-to-develop-crispr-based-mutation-resistant-avian-flu-therapeutic 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seek-labs-receives-2-million-usda-grant-to-develop-crispr-based-mutation-resistant-avian-flu-therapeutic 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-secures-australian-patent-for-novel-gene-therapy-targeting-motor-neuron-diseases 2026-02-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klotho-neurosciences-secures-australian-patent-for-novel-gene-therapy-targeting-motor-neuron-diseases 2026-02-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-becomes-first-u-s-institution-to-deploy-magnetic-nanoparticle-hyperthermia-technology-for-cancer-research 2026-02-17T21:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-becomes-first-u-s-institution-to-deploy-magnetic-nanoparticle-hyperthermia-technology-for-cancer-research 2026-02-17T21:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/calibr-skaggs-and-kainomyx-launch-gates-foundation-backed-collaboration-to-develop-novel-antimalarial-drugs-targeting-parasite-cytoskeleton 2026-02-17T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calibr-skaggs-and-kainomyx-launch-gates-foundation-backed-collaboration-to-develop-novel-antimalarial-drugs-targeting-parasite-cytoskeleton 2026-02-17T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/rna-targeting-small-molecules-emerge-as-new-frontier-in-drug-discovery-with-major-pharma-partnerships 2026-02-17T21:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-targeting-small-molecules-emerge-as-new-frontier-in-drug-discovery-with-major-pharma-partnerships 2026-02-17T21:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-develop-nanoparticle-based-gene-editing-platform-for-cystic-fibrosis-treatment 2026-02-17T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-researchers-develop-nanoparticle-based-gene-editing-platform-for-cystic-fibrosis-treatment 2026-02-17T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-faces-growing-revenue-pressures-from-pricing-and-reimbursement-delays 2026-02-17T21:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-faces-growing-revenue-pressures-from-pricing-and-reimbursement-delays 2026-02-17T21:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-city-partners-launch-integrated-theranostics-platform-for-adult-and-pediatric-patients 2026-02-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kansas-city-partners-launch-integrated-theranostics-platform-for-adult-and-pediatric-patients 2026-02-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/fred-hutch-scientists-develop-first-human-monoclonal-antibodies-to-block-epstein-barr-virus-infection 2026-02-17T21:02:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fred-hutch-scientists-develop-first-human-monoclonal-antibodies-to-block-epstein-barr-virus-infection 2026-02-17T21:02:17+00:00 hourly 0.9 https://trial.medpath.com/news/terns-pharmaceuticals-gains-institutional-interest-as-stock-surges-830-following-pipeline-updates 2026-02-17T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terns-pharmaceuticals-gains-institutional-interest-as-stock-surges-830-following-pipeline-updates 2026-02-17T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/largest-metabolomic-study-of-car-t-cell-therapy-reveals-new-biomarkers-for-predicting-severe-neurotoxicity 2026-02-17T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/largest-metabolomic-study-of-car-t-cell-therapy-reveals-new-biomarkers-for-predicting-severe-neurotoxicity 2026-02-17T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-reports-breakthrough-primate-study-results-for-novel-aml-therapeutic-oncotox-aml 2026-02-17T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-reports-breakthrough-primate-study-results-for-novel-aml-therapeutic-oncotox-aml 2026-02-17T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/cyrano-therapeutics-reports-positive-phase-2-results-for-cyr-064-in-persistent-post-viral-smell-loss 2026-02-17T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyrano-therapeutics-reports-positive-phase-2-results-for-cyr-064-in-persistent-post-viral-smell-loss 2026-02-17T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-completes-acquisition-of-recipharm-israel-and-forms-strategic-cdmo-partnership 2026-02-17T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-immunotherapeutics-completes-acquisition-of-recipharm-israel-and-forms-strategic-cdmo-partnership 2026-02-17T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/texas-community-cancer-center-launches-first-car-t-program-outside-hospital-setting 2026-02-17T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-community-cancer-center-launches-first-car-t-program-outside-hospital-setting 2026-02-17T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-partners-with-drake-rayden-foundation-to-manufacture-aav-gene-therapy-for-rare-nkh-disease 2026-02-17T17:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-partners-with-drake-rayden-foundation-to-manufacture-aav-gene-therapy-for-rare-nkh-disease 2026-02-17T17:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/essential-pharma-acquires-ventavis-for-primary-pulmonary-hypertension-from-bayer-ag 2026-02-17T17:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essential-pharma-acquires-ventavis-for-primary-pulmonary-hypertension-from-bayer-ag 2026-02-17T17:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-s-doc1021-clears-first-safety-review-in-phase-2-glioblastoma-trial 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-s-doc1021-clears-first-safety-review-in-phase-2-glioblastoma-trial 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-partners-with-queensland-university-to-develop-ai-driven-cancer-therapeutics-for-chemotherapy-resistant-lung-cancer 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-partners-with-queensland-university-to-develop-ai-driven-cancer-therapeutics-for-chemotherapy-resistant-lung-cancer 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-appoints-brian-piper-as-cfo-ahead-of-key-clinical-data-readouts 2026-02-17T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-appoints-brian-piper-as-cfo-ahead-of-key-clinical-data-readouts 2026-02-17T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/retia-medical-receives-fda-clearance-for-argos-infinity-cardiovascular-intelligence-platform 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retia-medical-receives-fda-clearance-for-argos-infinity-cardiovascular-intelligence-platform 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/portal-diabetes-receives-fda-breakthrough-designation-for-implantable-insulin-pump-system 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-diabetes-receives-fda-breakthrough-designation-for-implantable-insulin-pump-system 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-tirabrutinib-nda-for-rare-brain-lymphoma-under-accelerated-approval-pathway 2026-02-17T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-tirabrutinib-nda-for-rare-brain-lymphoma-under-accelerated-approval-pathway 2026-02-17T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-bristol-myers-squibb-s-iberdomide-nda-for-multiple-myeloma-testing-new-regulatory-flexibility 2026-02-17T17:02:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-bristol-myers-squibb-s-iberdomide-nda-for-multiple-myeloma-testing-new-regulatory-flexibility 2026-02-17T17:02:26+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-advances-novel-sik2-inhibitors-for-inflammatory-bowel-disease-with-dual-anti-inflammatory-and-mucosal-healing-mechanism 2026-02-17T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-advances-novel-sik2-inhibitors-for-inflammatory-bowel-disease-with-dual-anti-inflammatory-and-mucosal-healing-mechanism 2026-02-17T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/instanosis-receives-fda-breakthrough-device-designation-for-rapid-xylazine-urine-test 2026-02-17T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/instanosis-receives-fda-breakthrough-device-designation-for-rapid-xylazine-urine-test 2026-02-17T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-advances-ultra-long-acting-hiv-pipeline-with-third-generation-integrase-inhibitor-vh184-data-at-croi-2026 2026-02-17T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-advances-ultra-long-acting-hiv-pipeline-with-third-generation-integrase-inhibitor-vh184-data-at-croi-2026 2026-02-17T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-drug-amd3100-overcomes-immunotherapy-resistance-in-rare-liver-cancer 2026-02-17T17:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-drug-amd3100-overcomes-immunotherapy-resistance-in-rare-liver-cancer 2026-02-17T17:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/salipro-biotech-secures-key-u-s-patent-for-membrane-protein-platform-extending-protection-until-2042 2026-02-17T13:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salipro-biotech-secures-key-u-s-patent-for-membrane-protein-platform-extending-protection-until-2042 2026-02-17T13:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-teva-s-duvakitug-shows-sustained-efficacy-in-phase-2b-maintenance-study-for-inflammatory-bowel-disease 2026-02-17T13:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-teva-s-duvakitug-shows-sustained-efficacy-in-phase-2b-maintenance-study-for-inflammatory-bowel-disease 2026-02-17T13:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/circio-s-circvec-platform-achieves-50-fold-gene-expression-enhancement-in-eye-disease-applications 2026-02-17T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circio-s-circvec-platform-achieves-50-fold-gene-expression-enhancement-in-eye-disease-applications 2026-02-17T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-appoints-cancer-researcher-mark-dawson-to-lead-pharma-research-division 2026-02-17T13:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-appoints-cancer-researcher-mark-dawson-to-lead-pharma-research-division 2026-02-17T13:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-and-leadxpro-partner-to-accelerate-ai-driven-drug-discovery-for-challenging-membrane-proteins 2026-02-17T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclera-and-leadxpro-partner-to-accelerate-ai-driven-drug-discovery-for-challenging-membrane-proteins 2026-02-17T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/teijin-and-aska-pharmaceutical-partner-to-develop-ai-driven-gynecological-therapeutics 2026-02-17T13:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teijin-and-aska-pharmaceutical-partner-to-develop-ai-driven-gynecological-therapeutics 2026-02-17T13:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/beactica-secures-eur2-5-million-eic-grant-to-advance-first-in-class-glioblastoma-therapy-bea-17-toward-clinical-trials 2026-02-17T13:02:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beactica-secures-eur2-5-million-eic-grant-to-advance-first-in-class-glioblastoma-therapy-bea-17-toward-clinical-trials 2026-02-17T13:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/prognica-labs-and-nextgen-immuno-therapeutics-form-strategic-partnership-to-advance-ai-powered-precision-immunology 2026-02-17T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prognica-labs-and-nextgen-immuno-therapeutics-form-strategic-partnership-to-advance-ai-powered-precision-immunology 2026-02-17T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-revoking-safety-status-of-processed-carbohydrates-as-health-industry-faces-major-regulatory-and-corporate-shifts 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-considers-revoking-safety-status-of-processed-carbohydrates-as-health-industry-faces-major-regulatory-and-corporate-shifts 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/danaher-acquires-masimo-for-9-9-billion-to-expand-patient-monitoring-portfolio 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danaher-acquires-masimo-for-9-9-billion-to-expand-patient-monitoring-portfolio 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/oeb-6-emerges-as-new-manufacturing-standard-for-ultra-potent-oncology-drugs-and-adcs 2026-02-17T03:01:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oeb-6-emerges-as-new-manufacturing-standard-for-ultra-potent-oncology-drugs-and-adcs 2026-02-17T03:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-withdraws-anti-copycat-policy-as-eu-closes-antitrust-investigation 2026-02-17T01:01:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edwards-lifesciences-withdraws-anti-copycat-policy-as-eu-closes-antitrust-investigation 2026-02-17T01:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-veterinary-regulator-confirms-safety-profile-of-canine-osteoarthritis-drug-librela-following-comprehensive-review 2026-02-16T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-veterinary-regulator-confirms-safety-profile-of-canine-osteoarthritis-drug-librela-following-comprehensive-review 2026-02-16T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/single-dmt-dose-shows-rapid-lasting-antidepressant-effects-in-treatment-resistant-depression-trial 2026-02-16T21:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dmt-dose-shows-rapid-lasting-antidepressant-effects-in-treatment-resistant-depression-trial 2026-02-16T21:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/tozaro-secures-ps6-million-to-reduce-gene-therapy-manufacturing-costs-with-smart-polymer-platform 2026-02-16T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tozaro-secures-ps6-million-to-reduce-gene-therapy-manufacturing-costs-with-smart-polymer-platform 2026-02-16T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/zemcelpro-receives-nub-status-1-in-germany-enabling-immediate-hospital-reimbursement-applications 2026-02-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zemcelpro-receives-nub-status-1-in-germany-enabling-immediate-hospital-reimbursement-applications 2026-02-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-retevmo-shows-significant-event-free-survival-benefit-in-early-stage-ret-fusion-positive-lung-cancer 2026-02-16T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-retevmo-shows-significant-event-free-survival-benefit-in-early-stage-ret-fusion-positive-lung-cancer 2026-02-16T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-strengthens-leadership-team-with-three-key-appointments-to-advance-dna-damage-response-pipeline 2026-02-16T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artios-pharma-strengthens-leadership-team-with-three-key-appointments-to-advance-dna-damage-response-pipeline 2026-02-16T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/lex-diagnostics-receives-fda-510-k-clearance-for-ultra-fast-point-of-care-pcr-system 2026-02-16T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lex-diagnostics-receives-fda-510-k-clearance-for-ultra-fast-point-of-care-pcr-system 2026-02-16T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-foxg1-gene-therapy-for-clinical-trials-in-rare-neurodevelopmental-disorder 2026-02-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-foxg1-gene-therapy-for-clinical-trials-in-rare-neurodevelopmental-disorder 2026-02-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-report-first-case-of-type-2-diabetes-reversal-using-stem-cell-therapy 2026-02-16T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-report-first-case-of-type-2-diabetes-reversal-using-stem-cell-therapy 2026-02-16T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-consortium-secures-eur23-5-million-to-develop-next-generation-minimally-invasive-brain-surgery-technologies 2026-02-16T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seismic-consortium-secures-eur23-5-million-to-develop-next-generation-minimally-invasive-brain-surgery-technologies 2026-02-16T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-s-ella-platform-receives-ce-ivd-marking-expanding-rapid-immunoassay-access-in-european-clinical-laboratories 2026-02-16T13:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-s-ella-platform-receives-ce-ivd-marking-expanding-rapid-immunoassay-access-in-european-clinical-laboratories 2026-02-16T13:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/harness-therapeutics-advances-first-in-class-huntington-s-disease-drug-hrn001-toward-clinical-trials 2026-02-16T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harness-therapeutics-advances-first-in-class-huntington-s-disease-drug-hrn001-toward-clinical-trials 2026-02-16T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-e2086-receives-orphan-drug-designation-in-japan-for-narcolepsy-treatment 2026-02-16T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-s-e2086-receives-orphan-drug-designation-in-japan-for-narcolepsy-treatment 2026-02-16T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-raises-400m-to-advance-first-in-class-multiple-sclerosis-therapy-toward-commercial-launch 2026-02-16T13:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-raises-400m-to-advance-first-in-class-multiple-sclerosis-therapy-toward-commercial-launch 2026-02-16T13:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-partners-with-lifotronic-technology-to-expand-global-immunoassay-portfolio 2026-02-16T09:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidelortho-partners-with-lifotronic-technology-to-expand-global-immunoassay-portfolio 2026-02-16T09:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-s-novel-trispecific-antibody-cs2009-receives-fda-clearance-for-phase-ii-trial-in-advanced-solid-tumors 2026-02-16T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-s-novel-trispecific-antibody-cs2009-receives-fda-clearance-for-phase-ii-trial-in-advanced-solid-tumors 2026-02-16T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-launches-pantracer-pro-to-streamline-advanced-solid-tumor-testing 2026-02-15T21:02:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogenomics-launches-pantracer-pro-to-streamline-advanced-solid-tumor-testing 2026-02-15T21:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/uae-partners-with-insilico-medicine-to-launch-ai-driven-drug-discovery-initiative 2026-02-15T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-partners-with-insilico-medicine-to-launch-ai-driven-drug-discovery-initiative 2026-02-15T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/phathom-pharmaceuticals-refocuses-on-gastroenterology-projects-profitability-by-second-half-2026 2026-02-15T12:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-refocuses-on-gastroenterology-projects-profitability-by-second-half-2026 2026-02-15T12:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/iran-advances-to-7th-place-globally-in-regenerative-medicine-with-six-new-atmp-approvals 2026-02-15T12:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-advances-to-7th-place-globally-in-regenerative-medicine-with-six-new-atmp-approvals 2026-02-15T12:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/oncores-medical-raises-a-27-million-to-advance-real-time-breast-cancer-surgery-imaging-technology 2026-02-15T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncores-medical-raises-a-27-million-to-advance-real-time-breast-cancer-surgery-imaging-technology 2026-02-15T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-world-s-largest-mental-health-study-to-develop-personalized-treatments-for-severe-mental-illness 2026-02-15T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-world-s-largest-mental-health-study-to-develop-personalized-treatments-for-severe-mental-illness 2026-02-15T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/alkem-laboratories-enters-cardiovascular-device-market-with-eur99-4-million-occlutech-acquisition 2026-02-14T21:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkem-laboratories-enters-cardiovascular-device-market-with-eur99-4-million-occlutech-acquisition 2026-02-14T21:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-licenses-gpcr-targeted-program-to-investment-firm-backed-spin-out-company 2026-02-14T21:01:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-licenses-gpcr-targeted-program-to-investment-firm-backed-spin-out-company 2026-02-14T21:01:31+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-fda-approval-for-generic-ammonium-lactate-cream-for-dry-skin-conditions 2026-02-14T17:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-fda-approval-for-generic-ammonium-lactate-cream-for-dry-skin-conditions 2026-02-14T17:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-confirms-single-pivotal-study-standard-for-drug-approval-accelerating-cinclus-pharma-s-gerd-treatment-path 2026-02-14T04:40:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-confirms-single-pivotal-study-standard-for-drug-approval-accelerating-cinclus-pharma-s-gerd-treatment-path 2026-02-14T04:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-raises-316-3-million-in-public-offering-to-advance-blood-cancer-therapeutics-pipeline 2026-02-14T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galecto-raises-316-3-million-in-public-offering-to-advance-blood-cancer-therapeutics-pipeline 2026-02-14T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-pivots-to-international-markets-after-fda-rejects-flu-vaccine-application 2026-02-14T04:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-pivots-to-international-markets-after-fda-rejects-flu-vaccine-application 2026-02-14T04:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/deuterium-depletion-shows-promise-as-novel-cancer-therapy-through-gene-expression-modulation 2026-02-14T04:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deuterium-depletion-shows-promise-as-novel-cancer-therapy-through-gene-expression-modulation 2026-02-14T04:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/nk-cell-engager-development-faces-mounting-setbacks-as-beone-medicines-and-novartis-discontinue-programs 2026-02-14T04:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nk-cell-engager-development-faces-mounting-setbacks-as-beone-medicines-and-novartis-discontinue-programs 2026-02-14T04:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-therapies-enable-long-term-survival-in-multiple-myeloma-patients-through-second-stem-cell-transplants 2026-02-13T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-therapies-enable-long-term-survival-in-multiple-myeloma-patients-through-second-stem-cell-transplants 2026-02-13T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-and-acist-medical-systems-launch-next-generation-acist-pro-diagnostic-system-in-europe 2026-02-13T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-and-acist-medical-systems-launch-next-generation-acist-pro-diagnostic-system-in-europe 2026-02-13T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-multi-target-ibd-strategy-with-combination-therapies-and-subcutaneous-skyrizi-data-expected 2026-02-13T21:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-multi-target-ibd-strategy-with-combination-therapies-and-subcutaneous-skyrizi-data-expected 2026-02-13T21:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-study-confirms-six-month-oral-tb-regimens-reduce-costs-while-improving-outcomes-for-drug-resistant-cases 2026-02-13T21:02:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icmr-study-confirms-six-month-oral-tb-regimens-reduce-costs-while-improving-outcomes-for-drug-resistant-cases 2026-02-13T21:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-and-wy-biotech-launch-joint-venture-trimmune-to-advance-cancer-immunotherapy-hcw11-006 2026-02-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-and-wy-biotech-launch-joint-venture-trimmune-to-advance-cancer-immunotherapy-hcw11-006 2026-02-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-withdrawal-of-levamisole-medicines-from-eu-market-due-to-serious-brain-side-effects 2026-02-13T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-withdrawal-of-levamisole-medicines-from-eu-market-due-to-serious-brain-side-effects 2026-02-13T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-partners-with-insilico-medicine-for-ai-drug-discovery-advances-complement-inhibitor-to-clinical-trials 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-partners-with-insilico-medicine-for-ai-drug-discovery-advances-complement-inhibitor-to-clinical-trials 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-s-acrotech-receives-fda-approval-for-adquey-first-non-steroidal-pde4-inhibitor-for-atopic-dermatitis 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-s-acrotech-receives-fda-approval-for-adquey-first-non-steroidal-pde4-inhibitor-for-atopic-dermatitis 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/nasus-pharma-raises-15-million-to-advance-needle-free-epinephrine-treatment-for-anaphylaxis 2026-02-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasus-pharma-raises-15-million-to-advance-needle-free-epinephrine-treatment-for-anaphylaxis 2026-02-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biologics-presents-preclinical-data-on-novel-pb-223-adc-targeting-truncated-core-2-glycans-in-solid-tumors 2026-02-13T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biologics-presents-preclinical-data-on-novel-pb-223-adc-targeting-truncated-core-2-glycans-in-solid-tumors 2026-02-13T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biomed-launches-120-patient-study-to-validate-3d-cell-culture-platform-for-precision-cancer-treatment 2026-02-13T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-biomed-launches-120-patient-study-to-validate-3d-cell-culture-platform-for-precision-cancer-treatment 2026-02-13T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-breztri-shows-significant-lung-function-improvements-in-phase-iii-asthma-trials 2026-02-13T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-breztri-shows-significant-lung-function-improvements-in-phase-iii-asthma-trials 2026-02-13T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-expands-orlynvah-market-access-while-fda-requires-additional-clinical-trial-for-step-down-therapy 2026-02-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-expands-orlynvah-market-access-while-fda-requires-additional-clinical-trial-for-step-down-therapy 2026-02-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-integration-and-ps45-million-investment-signal-new-era-for-alzheimer-s-drug-discovery 2026-02-13T12:38:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-integration-and-ps45-million-investment-signal-new-era-for-alzheimer-s-drug-discovery 2026-02-13T12:38:50+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-institute-launches-multi-cancer-blood-test-trial-at-eight-centers-nationwide 2026-02-13T08:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-cancer-institute-launches-multi-cancer-blood-test-trial-at-eight-centers-nationwide 2026-02-13T08:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-receives-20m-milestone-as-iqirvo-exceeds-200m-sales-threshold-in-first-year 2026-02-13T04:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-receives-20m-milestone-as-iqirvo-exceeds-200m-sales-threshold-in-first-year 2026-02-13T04:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/japan-grants-world-first-pharmaceutical-approval-for-human-milk-based-fortifier-in-neonatal-care 2026-02-13T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-grants-world-first-pharmaceutical-approval-for-human-milk-based-fortifier-in-neonatal-care 2026-02-13T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-phase-3-trial-of-ibi354-her2-adc-for-first-line-her2-positive-breast-cancer-treatment 2026-02-13T04:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-initiates-phase-3-trial-of-ibi354-her2-adc-for-first-line-her2-positive-breast-cancer-treatment 2026-02-13T04:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-bocunebart-meets-primary-endpoint-in-phase-iib-migraine-prevention-trial 2026-02-13T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-bocunebart-meets-primary-endpoint-in-phase-iib-migraine-prevention-trial 2026-02-13T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/neuroendocrine-tumor-pipeline-shows-promise-with-75-therapies-in-development-and-recent-fda-approvals 2026-02-13T04:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroendocrine-tumor-pipeline-shows-promise-with-75-therapies-in-development-and-recent-fda-approvals 2026-02-13T04:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-withdraws-translarna-nda-for-duchenne-muscular-dystrophy-following-fda-feedback 2026-02-13T04:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-withdraws-translarna-nda-for-duchenne-muscular-dystrophy-following-fda-feedback 2026-02-13T04:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-first-whim-syndrome-treatment 2026-02-13T04:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-of-first-whim-syndrome-treatment 2026-02-13T04:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-partners-with-median-technologies-to-integrate-fda-cleared-ai-lung-cancer-screening-tool 2026-02-13T04:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-partners-with-median-technologies-to-integrate-fda-cleared-ai-lung-cancer-screening-tool 2026-02-13T04:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-s-lanifibranor-achieves-dual-endpoints-in-nash-trial-analysts-project-2-6b-peak-sales 2026-02-13T01:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-s-lanifibranor-achieves-dual-endpoints-in-nash-trial-analysts-project-2-6b-peak-sales 2026-02-13T01:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-challenges-medicare-price-controls-on-botox-citing-plasma-derived-product-exemption 2026-02-12T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-challenges-medicare-price-controls-on-botox-citing-plasma-derived-product-exemption 2026-02-12T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-finds-no-link-between-covid-19-mrna-vaccination-during-pregnancy-and-neurodevelopmental-disorders-in-children 2026-02-12T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-study-finds-no-link-between-covid-19-mrna-vaccination-during-pregnancy-and-neurodevelopmental-disorders-in-children 2026-02-12T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-begins-phase-1-trial-of-universal-flu-vaccine-targeting-all-strains 2026-02-12T21:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centivax-begins-phase-1-trial-of-universal-flu-vaccine-targeting-all-strains 2026-02-12T21:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-appoints-randy-teel-as-ceo-following-first-successful-protac-pivotal-trial 2026-02-12T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-appoints-randy-teel-as-ceo-following-first-successful-protac-pivotal-trial 2026-02-12T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/biolife-solutions-expands-into-500-million-cytokines-market-through-exclusive-qkine-partnership 2026-02-12T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolife-solutions-expands-into-500-million-cytokines-market-through-exclusive-qkine-partnership 2026-02-12T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-establishes-dermatology-subsidiary-ardia-to-advance-novel-psoriasis-treatment-dia-615 2026-02-12T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-establishes-dermatology-subsidiary-ardia-to-advance-novel-psoriasis-treatment-dia-615 2026-02-12T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/zeon-corporation-invests-in-digital-chemistry-pioneer-chemify-to-accelerate-automated-drug-discovery 2026-02-12T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeon-corporation-invests-in-digital-chemistry-pioneer-chemify-to-accelerate-automated-drug-discovery 2026-02-12T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-expands-global-patent-protection-for-ot-101-tgf-b-antisense-therapy-across-cns-and-neurology-applications 2026-02-12T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-expands-global-patent-protection-for-ot-101-tgf-b-antisense-therapy-across-cns-and-neurology-applications 2026-02-12T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/discus-trial-results-prompt-nhs-to-reduce-chemotherapy-cycles-for-advanced-bladder-cancer 2026-02-12T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/discus-trial-results-prompt-nhs-to-reduce-chemotherapy-cycles-for-advanced-bladder-cancer 2026-02-12T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-s-ai-powered-alloheme-test-detects-aml-and-mds-relapse-41-days-earlier-than-standard-methods 2026-02-12T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-s-ai-powered-alloheme-test-detects-aml-and-mds-relapse-41-days-earlier-than-standard-methods 2026-02-12T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/apertura-gene-therapy-launches-open-aperture-program-to-democratize-access-to-cns-targeting-aav-capsid 2026-02-12T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apertura-gene-therapy-launches-open-aperture-program-to-democratize-access-to-cns-targeting-aav-capsid 2026-02-12T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-files-orphan-drug-application-for-nv-387-mpox-treatment-amid-current-therapy-failures 2026-02-12T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-files-orphan-drug-application-for-nv-387-mpox-treatment-amid-current-therapy-failures 2026-02-12T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/totus-medicines-to-present-updated-phase-1-data-for-novel-covalent-pi3ka-inhibitor-tos-358-at-esmo-tat-congress 2026-02-12T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/totus-medicines-to-present-updated-phase-1-data-for-novel-covalent-pi3ka-inhibitor-tos-358-at-esmo-tat-congress 2026-02-12T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/grace-therapeutics-awaits-fda-decision-on-gtx-104-for-aneurysmal-subarachnoid-hemorrhage-with-april-2026-pdufa-date 2026-02-12T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grace-therapeutics-awaits-fda-decision-on-gtx-104-for-aneurysmal-subarachnoid-hemorrhage-with-april-2026-pdufa-date 2026-02-12T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-infigratinib-achieves-breakthrough-results-in-phase-3-achondroplasia-trial 2026-02-12T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-oral-infigratinib-achieves-breakthrough-results-in-phase-3-achondroplasia-trial 2026-02-12T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/encora-therapeutics-receives-fda-510-k-clearance-for-wearable-essential-tremor-device 2026-02-12T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/encora-therapeutics-receives-fda-510-k-clearance-for-wearable-essential-tremor-device 2026-02-12T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-dwarfism-drug-infigratinib-achieves-best-in-class-results-in-pivotal-achondroplasia-trial 2026-02-12T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-oral-dwarfism-drug-infigratinib-achieves-best-in-class-results-in-pivotal-achondroplasia-trial 2026-02-12T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/neupulse-secures-ps3-million-to-advance-tourette-syndrome-wearable-device-toward-2026-launch 2026-02-12T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neupulse-secures-ps3-million-to-advance-tourette-syndrome-wearable-device-toward-2026-launch 2026-02-12T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/biological-e-receives-who-phase-ii-pre-qualification-for-novel-oral-polio-vaccine-type-2 2026-02-12T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biological-e-receives-who-phase-ii-pre-qualification-for-novel-oral-polio-vaccine-type-2 2026-02-12T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-99mtc-maraciclatide-for-interstitial-lung-disease-imaging 2026-02-12T13:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-99mtc-maraciclatide-for-interstitial-lung-disease-imaging 2026-02-12T13:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/valar-labs-publishes-ai-breakthrough-for-pancreatic-cancer-treatment-selection-in-journal-of-clinical-oncology 2026-02-12T09:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valar-labs-publishes-ai-breakthrough-for-pancreatic-cancer-treatment-selection-in-journal-of-clinical-oncology 2026-02-12T09:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-receives-fda-clearance-for-phase-2-trial-of-novel-anti-fibrotic-drug-ak3280-in-idiopathic-pulmonary-fibrosis 2026-02-12T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-receives-fda-clearance-for-phase-2-trial-of-novel-anti-fibrotic-drug-ak3280-in-idiopathic-pulmonary-fibrosis 2026-02-12T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-genetic-mechanism-behind-rare-blood-clotting-in-johnson-johnson-and-astrazeneca-covid-vaccines 2026-02-12T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-genetic-mechanism-behind-rare-blood-clotting-in-johnson-johnson-and-astrazeneca-covid-vaccines 2026-02-12T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novocure-s-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:02:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novocure-s-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warnings-over-sexual-enhancement-products-containing-undeclared-prescription-drug-ingredients 2026-02-12T05:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warnings-over-sexual-enhancement-products-containing-undeclared-prescription-drug-ingredients 2026-02-12T05:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharmap-2026-to-showcase-patient-centric-medicine-and-regulatory-harmonization-in-amsterdam 2026-02-12T02:30:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmap-2026-to-showcase-patient-centric-medicine-and-regulatory-harmonization-in-amsterdam 2026-02-12T02:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/speed-based-brain-training-reduces-dementia-risk-by-25-in-20-year-clinical-trial 2026-02-12T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/speed-based-brain-training-reduces-dementia-risk-by-25-in-20-year-clinical-trial 2026-02-12T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/pl-bioscience-secures-japan-pmda-certification-for-cell-culture-media-advancing-regenerative-medicine-development 2026-02-12T01:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pl-bioscience-secures-japan-pmda-certification-for-cell-culture-media-advancing-regenerative-medicine-development 2026-02-12T01:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/crystalys-therapeutics-appoints-former-horizon-ceo-tim-walbert-to-board-as-gout-drug-advances-through-phase-3-trials 2026-02-12T01:03:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crystalys-therapeutics-appoints-former-horizon-ceo-tim-walbert-to-board-as-gout-drug-advances-through-phase-3-trials 2026-02-12T01:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/cardiometabolic-trial-design-evolves-beyond-weight-loss-to-address-complex-disease-spectrum 2026-02-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiometabolic-trial-design-evolves-beyond-weight-loss-to-address-complex-disease-spectrum 2026-02-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-inc-advances-radiogel-r-precision-radionuclide-therapy-toward-fda-clinical-trials 2026-02-11T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivos-inc-advances-radiogel-r-precision-radionuclide-therapy-toward-fda-clinical-trials 2026-02-11T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/claudin18-2-adc-race-intensifies-as-astrazeneca-prepares-pivotal-data-while-chinese-competitors-advance 2026-02-11T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/claudin18-2-adc-race-intensifies-as-astrazeneca-prepares-pivotal-data-while-chinese-competitors-advance 2026-02-11T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/slamf6-emerges-as-novel-immune-checkpoint-target-for-cancer-immunotherapy 2026-02-11T21:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/slamf6-emerges-as-novel-immune-checkpoint-target-for-cancer-immunotherapy 2026-02-11T21:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-delivery-systems-initiates-first-in-human-phase-1-trial-of-ivmed-85-for-myopia-prevention 2026-02-11T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-delivery-systems-initiates-first-in-human-phase-1-trial-of-ivmed-85-for-myopia-prevention 2026-02-11T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/oregon-state-researchers-develop-gold-nanoparticles-for-safe-low-power-melanoma-therapy 2026-02-11T21:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oregon-state-researchers-develop-gold-nanoparticles-for-safe-low-power-melanoma-therapy 2026-02-11T21:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/zura-bio-advances-dual-target-bispecific-tibulizumab-through-phase-2-trials-in-autoimmune-diseases 2026-02-11T21:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zura-bio-advances-dual-target-bispecific-tibulizumab-through-phase-2-trials-in-autoimmune-diseases 2026-02-11T21:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-advances-sevasemten-phase-3-trial-for-duchenne-muscular-dystrophy-with-enhanced-statistical-power 2026-02-11T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-advances-sevasemten-phase-3-trial-for-duchenne-muscular-dystrophy-with-enhanced-statistical-power 2026-02-11T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-and-healthy-extracts-form-strategic-partnership-to-scale-gel-based-nutraceutical-manufacturing 2026-02-11T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelteq-and-healthy-extracts-form-strategic-partnership-to-scale-gel-based-nutraceutical-manufacturing 2026-02-11T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-partners-with-datavant-to-enhance-real-world-data-connectivity-in-clinical-research 2026-02-11T21:01:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-partners-with-datavant-to-enhance-real-world-data-connectivity-in-clinical-research 2026-02-11T21:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulators-impose-major-restrictions-on-chikungunya-vaccine-following-fatal-adverse-events 2026-02-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulators-impose-major-restrictions-on-chikungunya-vaccine-following-fatal-adverse-events 2026-02-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-s-prolectin-m-achieves-100-viral-clearance-in-phase-2-trial 2026-02-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-s-prolectin-m-achieves-100-viral-clearance-in-phase-2-trial 2026-02-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-develop-advanced-human-spinal-cord-organoids-to-test-revolutionary-dancing-molecules-therapy 2026-02-11T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-scientists-develop-advanced-human-spinal-cord-organoids-to-test-revolutionary-dancing-molecules-therapy 2026-02-11T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-systasy-and-lmu-university-hospital-launch-ai-driven-collaboration-to-target-neutrophil-mediated-inflammatory-diseases 2026-02-11T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-systasy-and-lmu-university-hospital-launch-ai-driven-collaboration-to-target-neutrophil-mediated-inflammatory-diseases 2026-02-11T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-initiates-first-in-human-trial-of-stk-002-for-rare-genetic-eye-disease-adoa 2026-02-11T17:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-initiates-first-in-human-trial-of-stk-002-for-rare-genetic-eye-disease-adoa 2026-02-11T17:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-dose-therapeutics-launches-quickstrip-medical-cannabis-in-brazil-following-anvisa-approval 2026-02-11T17:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-dose-therapeutics-launches-quickstrip-medical-cannabis-in-brazil-following-anvisa-approval 2026-02-11T17:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-partners-with-orygen-for-phase-2-trial-of-novel-glutamate-targeting-drug-in-early-psychosis 2026-02-11T17:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denovo-biopharma-partners-with-orygen-for-phase-2-trial-of-novel-glutamate-targeting-drug-in-early-psychosis 2026-02-11T17:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/german-pharma-industry-warns-us-drug-price-regulations-could-delay-medicine-launches-in-europe 2026-02-11T13:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-pharma-industry-warns-us-drug-price-regulations-could-delay-medicine-launches-in-europe 2026-02-11T13:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-s-verekitug-shows-significant-efficacy-in-phase-2-severe-asthma-trial 2026-02-11T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upstream-bio-s-verekitug-shows-significant-efficacy-in-phase-2-severe-asthma-trial 2026-02-11T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-s-mb310-achieves-63-clinical-remission-rate-in-phase-1b-ulcerative-colitis-trial 2026-02-11T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiotica-s-mb310-achieves-63-clinical-remission-rate-in-phase-1b-ulcerative-colitis-trial 2026-02-11T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-therapeutics-initiates-phase-iia-trial-of-novel-acetylcholinesterase-inhibitor-at-004-for-acne-vulgaris 2026-02-11T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-therapeutics-initiates-phase-iia-trial-of-novel-acetylcholinesterase-inhibitor-at-004-for-acne-vulgaris 2026-02-11T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/erlysign-receives-fda-breakthrough-device-designation-for-revolutionary-saliva-based-oral-cancer-detection-test 2026-02-11T13:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erlysign-receives-fda-breakthrough-device-designation-for-revolutionary-saliva-based-oral-cancer-detection-test 2026-02-11T13:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-awaits-pivotal-seralutinib-data-for-pulmonary-arterial-hypertension-this-month 2026-02-11T13:02:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gossamer-bio-awaits-pivotal-seralutinib-data-for-pulmonary-arterial-hypertension-this-month 2026-02-11T13:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-reports-positive-phase-1b-results-for-oral-glp-1-agonist-elecoglipron-in-chinese-patients-with-obesity 2026-02-11T05:02:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eccogene-reports-positive-phase-1b-results-for-oral-glp-1-agonist-elecoglipron-in-chinese-patients-with-obesity 2026-02-11T05:02:26+00:00 hourly 0.9 https://trial.medpath.com/news/vesalio-secures-ce-mark-for-neurovascular-devices-targeting-cerebral-vasospasm-and-stroke-treatment 2026-02-11T05:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesalio-secures-ce-mark-for-neurovascular-devices-targeting-cerebral-vasospasm-and-stroke-treatment 2026-02-11T05:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-licenses-araris-aralinq-technology-for-next-generation-adc-development 2026-02-11T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-licenses-araris-aralinq-technology-for-next-generation-adc-development 2026-02-11T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/psma-pet-ct-guided-salvage-radiotherapy-shows-promising-5-year-outcomes-in-post-prostatectomy-patients 2026-02-11T01:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psma-pet-ct-guided-salvage-radiotherapy-shows-promising-5-year-outcomes-in-post-prostatectomy-patients 2026-02-11T01:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/thx-pharma-and-biocodex-forge-eur173-million-licensing-deal-for-rare-neurological-disease-treatments 2026-02-10T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thx-pharma-and-biocodex-forge-eur173-million-licensing-deal-for-rare-neurological-disease-treatments 2026-02-10T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-appoints-amy-walker-as-ceo-to-lead-commercial-growth-in-synthetic-dna-manufacturing 2026-02-10T21:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4basebio-appoints-amy-walker-as-ceo-to-lead-commercial-growth-in-synthetic-dna-manufacturing 2026-02-10T21:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-alzheimer-s-disease-in-first-neurodegenerative-application 2026-02-10T21:04:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-for-alzheimer-s-disease-in-first-neurodegenerative-application 2026-02-10T21:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/canary-speech-and-intermountain-health-launch-first-ai-driven-vocal-biomarker-study-for-multiple-sclerosis-detection 2026-02-10T21:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canary-speech-and-intermountain-health-launch-first-ai-driven-vocal-biomarker-study-for-multiple-sclerosis-detection 2026-02-10T21:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ipledge-rems-modifications-to-reduce-isotretinoin-access-barriers-while-maintaining-safety 2026-02-10T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ipledge-rems-modifications-to-reduce-isotretinoin-access-barriers-while-maintaining-safety 2026-02-10T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/bvi-s-finevision-hp-trifocal-iol-successfully-implanted-in-first-us-procedures-following-fda-approval 2026-02-10T21:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bvi-s-finevision-hp-trifocal-iol-successfully-implanted-in-first-us-procedures-following-fda-approval 2026-02-10T21:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-2b-trial-of-teverelix-for-advanced-prostate-cancer-patients-with-high-cardiovascular-risk 2026-02-10T21:01:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-phase-2b-trial-of-teverelix-for-advanced-prostate-cancer-patients-with-high-cardiovascular-risk 2026-02-10T21:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/active-biotech-s-tasquinimod-myelofibrosis-trial-resumes-after-fda-approval-of-protocol-amendment 2026-02-10T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/active-biotech-s-tasquinimod-myelofibrosis-trial-resumes-after-fda-approval-of-protocol-amendment 2026-02-10T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/nih-halts-rivaroxaban-arm-of-major-stroke-prevention-trial-due-to-safety-concerns 2026-02-10T21:01:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-halts-rivaroxaban-arm-of-major-stroke-prevention-trial-due-to-safety-concerns 2026-02-10T21:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-unveils-first-in-class-phase-3-data-for-novel-cat-and-birch-allergy-treatments-at-aaaai-2026 2026-02-10T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-unveils-first-in-class-phase-3-data-for-novel-cat-and-birch-allergy-treatments-at-aaaai-2026 2026-02-10T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-signs-five-year-strategic-agreement-with-mexico-for-mrna-manufacturing-and-vaccine-supply 2026-02-10T17:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-signs-five-year-strategic-agreement-with-mexico-for-mrna-manufacturing-and-vaccine-supply 2026-02-10T17:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/university-at-buffalo-researchers-develop-inhalable-nanoparticle-system-for-tuberculosis-treatment 2026-02-10T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-at-buffalo-researchers-develop-inhalable-nanoparticle-system-for-tuberculosis-treatment 2026-02-10T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-advances-mrgprx2-inhibitor-sep-631-to-clinical-testing-for-chronic-urticaria-and-mast-cell-disorders 2026-02-10T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septerna-advances-mrgprx2-inhibitor-sep-631-to-clinical-testing-for-chronic-urticaria-and-mast-cell-disorders 2026-02-10T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/arraypatch-secures-eur1-6m-in-first-close-of-seed-round-to-advance-microneedle-patch-for-nail-fungus-treatment 2026-02-10T17:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arraypatch-secures-eur1-6m-in-first-close-of-seed-round-to-advance-microneedle-patch-for-nail-fungus-treatment 2026-02-10T17:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/calbiotech-and-liquid-biosciences-form-strategic-partnership-to-advance-ai-driven-diagnostic-development 2026-02-10T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calbiotech-and-liquid-biosciences-form-strategic-partnership-to-advance-ai-driven-diagnostic-development 2026-02-10T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/qnovia-s-respirx-inhaled-nicotine-therapy-shows-promise-in-phase-1-trial-with-cigarette-like-delivery-speed 2026-02-10T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qnovia-s-respirx-inhaled-nicotine-therapy-shows-promise-in-phase-1-trial-with-cigarette-like-delivery-speed 2026-02-10T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/merck-partners-with-calla-lily-clinical-care-to-advance-novel-intravaginal-drug-delivery-platform 2026-02-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-partners-with-calla-lily-clinical-care-to-advance-novel-intravaginal-drug-delivery-platform 2026-02-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/iterion-therapeutics-initiates-first-in-class-wnt-b-catenin-inhibitor-trial-for-relapsed-osteosarcoma 2026-02-10T17:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterion-therapeutics-initiates-first-in-class-wnt-b-catenin-inhibitor-trial-for-relapsed-osteosarcoma 2026-02-10T17:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-gdnf-shows-superior-efficacy-over-semaglutide-in-preclinical-obesity-study 2026-02-10T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-gdnf-shows-superior-efficacy-over-semaglutide-in-preclinical-obesity-study 2026-02-10T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-secures-exclusive-ip-rights-for-circrna-based-alzheimer-s-blood-test-from-leading-research-institutions 2026-02-10T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-genomics-secures-exclusive-ip-rights-for-circrna-based-alzheimer-s-blood-test-from-leading-research-institutions 2026-02-10T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-missouri-launches-first-on-campus-radiopharmaceutical-clinical-trial-using-eye90-microspheres-for-liver-cancer 2026-02-10T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-missouri-launches-first-on-campus-radiopharmaceutical-clinical-trial-using-eye90-microspheres-for-liver-cancer 2026-02-10T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-engages-lifesci-capital-for-strategic-review-as-stock-surges-over-300 2026-02-10T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-engages-lifesci-capital-for-strategic-review-as-stock-surges-over-300 2026-02-10T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/daratumumab-demonstrates-76-reduction-in-relapse-risk-for-nmosd-in-phase-3-dawn-trial 2026-02-10T13:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daratumumab-demonstrates-76-reduction-in-relapse-risk-for-nmosd-in-phase-3-dawn-trial 2026-02-10T13:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/irbm-develops-novel-allosteric-inhibitor-targeting-zika-virus-protease-with-broad-flavivirus-potential 2026-02-10T13:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irbm-develops-novel-allosteric-inhibitor-targeting-zika-virus-protease-with-broad-flavivirus-potential 2026-02-10T13:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/claudin-18-2-targeted-therapy-market-set-to-exceed-800-million-by-2030-as-pipeline-expands-beyond-gastric-cancer 2026-02-10T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/claudin-18-2-targeted-therapy-market-set-to-exceed-800-million-by-2030-as-pipeline-expands-beyond-gastric-cancer 2026-02-10T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/gyala-therapeutics-launches-first-in-class-cd84-targeted-car-t-trial-for-relapsed-acute-leukemias 2026-02-10T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyala-therapeutics-launches-first-in-class-cd84-targeted-car-t-trial-for-relapsed-acute-leukemias 2026-02-10T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-institute-launches-preclinical-study-of-ivermectin-s-anticancer-properties 2026-02-10T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-cancer-institute-launches-preclinical-study-of-ivermectin-s-anticancer-properties 2026-02-10T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/yatiri-bio-achieves-100-accuracy-in-predicting-aml-drug-response-using-ai-driven-biomarker-platform 2026-02-10T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yatiri-bio-achieves-100-accuracy-in-predicting-aml-drug-response-using-ai-driven-biomarker-platform 2026-02-10T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/kainova-therapeutics-raises-32m-cad-to-advance-gpcr-targeting-cancer-and-inflammation-therapies 2026-02-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kainova-therapeutics-raises-32m-cad-to-advance-gpcr-targeting-cancer-and-inflammation-therapies 2026-02-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-partners-with-johns-hopkins-university-to-accelerate-early-stage-drug-discovery-programs 2026-02-10T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syngene-international-partners-with-johns-hopkins-university-to-accelerate-early-stage-drug-discovery-programs 2026-02-10T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-settles-90-million-patent-dispute-with-astellas-to-secure-mirabegron-market-access 2026-02-10T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-settles-90-million-patent-dispute-with-astellas-to-secure-mirabegron-market-access 2026-02-10T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-and-phlow-corp-launch-first-end-to-end-u-s-manufacturing-partnership-for-epinephrine-injection 2026-02-10T01:02:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-kabi-and-phlow-corp-launch-first-end-to-end-u-s-manufacturing-partnership-for-epinephrine-injection 2026-02-10T01:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/merrylife-biomedical-advances-tml-6-to-phase-2-following-positive-safety-results-in-alzheimer-s-disease-trial 2026-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merrylife-biomedical-advances-tml-6-to-phase-2-following-positive-safety-results-in-alzheimer-s-disease-trial 2026-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparingvision-completes-dosing-in-phase-i-ii-trial-for-gene-agnostic-retinitis-pigmentosa-therapy-spvn06 2026-02-09T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparingvision-completes-dosing-in-phase-i-ii-trial-for-gene-agnostic-retinitis-pigmentosa-therapy-spvn06 2026-02-09T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-advances-proof-of-concept-study-for-rare-pain-disorder-erythromelalgia 2026-02-09T21:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-advances-proof-of-concept-study-for-rare-pain-disorder-erythromelalgia 2026-02-09T21:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/diff-biotech-s-novel-nasal-spray-influenza-vaccine-receives-clinical-trial-approval-in-china 2026-02-09T21:03:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diff-biotech-s-novel-nasal-spray-influenza-vaccine-receives-clinical-trial-approval-in-china 2026-02-09T21:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/time-restricted-feeding-reduces-crohn-s-disease-activity-by-40-in-randomized-trial 2026-02-09T21:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/time-restricted-feeding-reduces-crohn-s-disease-activity-by-40-in-randomized-trial 2026-02-09T21:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/uv-smart-receives-first-ever-fda-clearance-for-uv-c-tee-probe-disinfection-system 2026-02-09T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uv-smart-receives-first-ever-fda-clearance-for-uv-c-tee-probe-disinfection-system 2026-02-09T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-krystal-biotech-s-kb707-gene-therapy-for-advanced-non-small-cell-lung-cancer 2026-02-09T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-krystal-biotech-s-kb707-gene-therapy-for-advanced-non-small-cell-lung-cancer 2026-02-09T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/quantx-biosciences-raises-85m-series-b-to-advance-oral-stat6-and-il-17-inhibitors 2026-02-09T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantx-biosciences-raises-85m-series-b-to-advance-oral-stat6-and-il-17-inhibitors 2026-02-09T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/aerska-secures-39m-series-a-to-advance-rna-brain-delivery-platform-for-neurological-diseases 2026-02-09T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerska-secures-39m-series-a-to-advance-rna-brain-delivery-platform-for-neurological-diseases 2026-02-09T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/nextpoint-therapeutics-receives-fda-clearance-for-first-in-class-b7-h7-targeted-t-cell-engager-npx372 2026-02-09T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextpoint-therapeutics-receives-fda-clearance-for-first-in-class-b7-h7-targeted-t-cell-engager-npx372 2026-02-09T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-dual-payload-adc-kh815-enters-clinical-trials-with-biodlink-manufacturing-support 2026-02-09T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-dual-payload-adc-kh815-enters-clinical-trials-with-biodlink-manufacturing-support 2026-02-09T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/cellarisbio-secures-patent-and-launches-micro-tag-platform-for-real-time-drug-target-engagement 2026-02-09T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellarisbio-secures-patent-and-launches-micro-tag-platform-for-real-time-drug-target-engagement 2026-02-09T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/transmedics-receives-fda-approval-for-landmark-heart-preservation-trial-to-challenge-standard-transplant-methods 2026-02-09T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transmedics-receives-fda-approval-for-landmark-heart-preservation-trial-to-challenge-standard-transplant-methods 2026-02-09T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-partners-with-clinical-stage-company-to-apply-ai-analysis-to-phase-2-metastatic-colorectal-cancer-trial-data 2026-02-09T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-partners-with-clinical-stage-company-to-apply-ai-analysis-to-phase-2-metastatic-colorectal-cancer-trial-data 2026-02-09T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-partners-with-german-center-for-infection-research-to-develop-next-generation-mrna-vaccines 2026-02-09T13:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-partners-with-german-center-for-infection-research-to-develop-next-generation-mrna-vaccines 2026-02-09T13:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/arecor-therapeutics-advances-ultra-concentrated-insulin-at278-toward-phase-ii-trial-in-2026 2026-02-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arecor-therapeutics-advances-ultra-concentrated-insulin-at278-toward-phase-ii-trial-in-2026 2026-02-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/breye-therapeutics-reports-promising-phase-1b-results-for-oral-diabetic-retinopathy-drug-danegaptide 2026-02-09T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breye-therapeutics-reports-promising-phase-1b-results-for-oral-diabetic-retinopathy-drug-danegaptide 2026-02-09T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/pandorum-technologies-secures-18m-series-b-to-advance-exosome-based-regenerative-therapies 2026-02-09T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pandorum-technologies-secures-18m-series-b-to-advance-exosome-based-regenerative-therapies 2026-02-09T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-partners-with-csl-in-328-million-deal-for-recombinant-polyclonal-igg-technology 2026-02-09T09:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memo-therapeutics-partners-with-csl-in-328-million-deal-for-recombinant-polyclonal-igg-technology 2026-02-09T09:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/hku-researchers-demonstrate-finerenone-s-potential-in-treating-premature-ovarian-insufficiency 2026-02-09T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-researchers-demonstrate-finerenone-s-potential-in-treating-premature-ovarian-insufficiency 2026-02-09T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-partners-with-evinova-to-deploy-ai-driven-clinical-trial-optimization-platform 2026-02-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-partners-with-evinova-to-deploy-ai-driven-clinical-trial-optimization-platform 2026-02-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-therapeutics-promotes-francis-wilson-to-chief-scientific-officer-to-lead-pre-cision-platform-development 2026-02-09T09:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-therapeutics-promotes-francis-wilson-to-chief-scientific-officer-to-lead-pre-cision-platform-development 2026-02-09T09:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-enters-critical-phase-following-immunoscape-partnership-and-december-2025-financing 2026-02-09T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-enters-critical-phase-following-immunoscape-partnership-and-december-2025-financing 2026-02-09T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/phytolon-receives-fda-approval-for-natural-beetroot-red-food-coloring-marking-major-regulatory-milestone 2026-02-09T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phytolon-receives-fda-approval-for-natural-beetroot-red-food-coloring-marking-major-regulatory-milestone 2026-02-09T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-expands-generic-medicine-portfolio-through-strategic-partnership-with-cadila 2026-02-09T05:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-expands-generic-medicine-portfolio-through-strategic-partnership-with-cadila 2026-02-09T05:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/wilson-disease-pipeline-shows-promise-with-alxn1840-completing-phase-iii-trial-and-five-companies-advancing-novel-therapies 2026-02-09T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wilson-disease-pipeline-shows-promise-with-alxn1840-completing-phase-iii-trial-and-five-companies-advancing-novel-therapies 2026-02-09T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-intuitive-surgical-s-da-vinci-5-system-for-advanced-cardiac-procedures 2026-02-09T01:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-intuitive-surgical-s-da-vinci-5-system-for-advanced-cardiac-procedures 2026-02-09T01:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-agonists-show-promise-in-reducing-sleep-apnea-risk-and-improving-cardiometabolic-outcomes 2026-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-agonists-show-promise-in-reducing-sleep-apnea-risk-and-improving-cardiometabolic-outcomes 2026-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-receives-11-procedural-observations-from-us-fda-at-telangana-manufacturing-facility 2026-02-08T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-receives-11-procedural-observations-from-us-fda-at-telangana-manufacturing-facility 2026-02-08T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-drive-technology-successfully-reverses-antibiotic-resistance-in-bacterial-populations 2026-02-08T05:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-drive-technology-successfully-reverses-antibiotic-resistance-in-bacterial-populations 2026-02-08T05:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-fda-clearance-for-two-key-facilities-following-successful-regulatory-inspections 2026-02-08T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-receives-fda-clearance-for-two-key-facilities-following-successful-regulatory-inspections 2026-02-08T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-solosec-shows-92-95-cure-rate-in-phase-3-trichomoniasis-trial-expanding-treatment-options-for-common-sti 2026-02-08T01:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-s-solosec-shows-92-95-cure-rate-in-phase-3-trichomoniasis-trial-expanding-treatment-options-for-common-sti 2026-02-08T01:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-tentative-fda-approvals-for-generic-tadalafil-and-testosterone-gel-targeting-2-9-billion-combined-market 2026-02-08T01:01:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-secures-tentative-fda-approvals-for-generic-tadalafil-and-testosterone-gel-targeting-2-9-billion-combined-market 2026-02-08T01:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-initiates-phase-i-trial-for-indigenous-kyasanur-forest-disease-vaccine 2026-02-07T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icmr-initiates-phase-i-trial-for-indigenous-kyasanur-forest-disease-vaccine 2026-02-07T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-scientists-develop-oral-compound-mic-628-to-reset-circadian-rhythms-and-combat-jet-lag 2026-02-07T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-scientists-develop-oral-compound-mic-628-to-reset-circadian-rhythms-and-combat-jet-lag 2026-02-07T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/smx-secures-250-million-capital-extension-through-2028-to-advance-supply-chain-verification-platform 2026-02-07T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smx-secures-250-million-capital-extension-through-2028-to-advance-supply-chain-verification-platform 2026-02-07T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-files-first-us-transdermal-patch-anda-for-rotigotine-targeting-112-million-market 2026-02-07T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-files-first-us-transdermal-patch-anda-for-rotigotine-targeting-112-million-market 2026-02-07T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/ps1bn-london-cancer-hub-expansion-approved-to-boost-uk-life-sciences-research 2026-02-07T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps1bn-london-cancer-hub-expansion-approved-to-boost-uk-life-sciences-research 2026-02-07T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/breckenridge-pharmaceutical-partners-with-medichem-solutions-to-expand-injectable-portfolio-for-hospital-markets 2026-02-07T01:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breckenridge-pharmaceutical-partners-with-medichem-solutions-to-expand-injectable-portfolio-for-hospital-markets 2026-02-07T01:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/lumosa-s-lt3001-shows-functional-improvements-in-phase-2-trials-for-acute-ischemic-stroke 2026-02-07T01:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumosa-s-lt3001-shows-functional-improvements-in-phase-2-trials-for-acute-ischemic-stroke 2026-02-07T01:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-imaging-enters-cell-therapy-manufacturing-with-microbubble-based-cell-selection-technology 2026-02-07T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-imaging-enters-cell-therapy-manufacturing-with-microbubble-based-cell-selection-technology 2026-02-07T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/hemex-health-receives-fda-breakthrough-device-designation-for-sickle-cell-disease-diagnostic-test 2026-02-07T01:01:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemex-health-receives-fda-breakthrough-device-designation-for-sickle-cell-disease-diagnostic-test 2026-02-07T01:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-completes-enrollment-in-phase-2b-trial-of-resomelagon-for-newly-diagnosed-rheumatoid-arthritis 2026-02-07T01:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-pharma-completes-enrollment-in-phase-2b-trial-of-resomelagon-for-newly-diagnosed-rheumatoid-arthritis 2026-02-07T01:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/cvs-health-expands-biosimilar-strategy-dropping-amgen-and-lilly-bone-disease-treatments-from-formularies 2026-02-06T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvs-health-expands-biosimilar-strategy-dropping-amgen-and-lilly-bone-disease-treatments-from-formularies 2026-02-06T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-required-to-provide-detailed-q1-q2-sameness-feedback-under-new-federal-law 2026-02-06T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-required-to-provide-detailed-q1-q2-sameness-feedback-under-new-federal-law 2026-02-06T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-and-entera-bio-expand-partnership-to-develop-first-oral-long-acting-pth-therapy-for-hypoparathyroidism 2026-02-06T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-and-entera-bio-expand-partnership-to-develop-first-oral-long-acting-pth-therapy-for-hypoparathyroidism 2026-02-06T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-classification-system-predicts-immunotherapy-response-in-liver-cancer-patients-with-b-catenin-mutations 2026-02-06T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-classification-system-predicts-immunotherapy-response-in-liver-cancer-patients-with-b-catenin-mutations 2026-02-06T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/delonix-bioworks-receives-dual-regulatory-clearance-for-novel-menb-vaccine-dx-104-in-china-and-australia 2026-02-06T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delonix-bioworks-receives-dual-regulatory-clearance-for-novel-menb-vaccine-dx-104-in-china-and-australia 2026-02-06T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/pulmovant-completes-enrollment-in-phase-2-trial-of-mosliciguat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2026-02-06T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmovant-completes-enrollment-in-phase-2-trial-of-mosliciguat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2026-02-06T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/priovant-s-brepocitinib-shows-significant-efficacy-in-rare-skin-disease-trial-advancing-to-phase-3 2026-02-06T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priovant-s-brepocitinib-shows-significant-efficacy-in-rare-skin-disease-trial-advancing-to-phase-3 2026-02-06T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/neurophet-receives-third-fda-510-k-clearance-for-ai-powered-alzheimer-s-imaging-analysis-software 2026-02-06T17:02:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurophet-receives-third-fda-510-k-clearance-for-ai-powered-alzheimer-s-imaging-analysis-software 2026-02-06T17:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-floods-super-bowl-2026-with-record-ad-presence-despite-fda-crackdown-threats 2026-02-06T13:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-floods-super-bowl-2026-with-record-ad-presence-despite-fda-crackdown-threats 2026-02-06T13:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-dedicated-3t-mri-system-for-neonatal-imaging 2026-02-06T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-dedicated-3t-mri-system-for-neonatal-imaging 2026-02-06T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/bc-platforms-partners-with-omicsbank-to-expand-access-to-multi-omics-data-from-india-and-uae 2026-02-06T09:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bc-platforms-partners-with-omicsbank-to-expand-access-to-multi-omics-data-from-india-and-uae 2026-02-06T09:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-secures-exclusive-rights-to-sky-labs-cuffless-blood-pressure-monitor-for-japan-market 2026-02-06T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-pharmaceutical-secures-exclusive-rights-to-sky-labs-cuffless-blood-pressure-monitor-for-japan-market 2026-02-06T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaresearch-receives-fda-clearance-for-phase-1-trial-of-nano-anticancer-drug-prd-101 2026-02-06T09:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaresearch-receives-fda-clearance-for-phase-1-trial-of-nano-anticancer-drug-prd-101 2026-02-06T09:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-phase-2-trial-of-mibavademab-for-functional-hypothalamic-amenorrhea 2026-02-06T09:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-advances-phase-2-trial-of-mibavademab-for-functional-hypothalamic-amenorrhea 2026-02-06T09:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-reports-progress-across-rna-therapy-pipeline-with-strong-financial-position 2026-02-06T09:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyc-therapeutics-reports-progress-across-rna-therapy-pipeline-with-strong-financial-position 2026-02-06T09:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-approves-velsipity-for-moderately-to-severely-active-ulcerative-colitis 2026-02-06T09:01:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-approves-velsipity-for-moderately-to-severely-active-ulcerative-colitis 2026-02-06T09:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-reports-strong-q2-2025-performance-with-pipeline-advances-and-raised-guidance 2026-02-06T05:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-reports-strong-q2-2025-performance-with-pipeline-advances-and-raised-guidance 2026-02-06T05:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/iit-bombay-develops-gentler-t-cell-recovery-method-to-enhance-car-t-cell-therapy-efficiency 2026-02-06T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-bombay-develops-gentler-t-cell-recovery-method-to-enhance-car-t-cell-therapy-efficiency 2026-02-06T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/fagron-expands-global-pharmaceutical-compounding-network-with-strategic-acquisitions-in-brazil-and-hungary 2026-02-06T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fagron-expands-global-pharmaceutical-compounding-network-with-strategic-acquisitions-in-brazil-and-hungary 2026-02-06T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-reports-six-year-data-showing-tralesinidase-alfa-preserves-cognitive-function-in-sanfilippo-syndrome-type-b 2026-02-06T01:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-reports-six-year-data-showing-tralesinidase-alfa-preserves-cognitive-function-in-sanfilippo-syndrome-type-b 2026-02-06T01:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-amtagvi-achieves-44-response-rate-in-advanced-melanoma-exceeding-clinical-trial-results 2026-02-06T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-amtagvi-achieves-44-response-rate-in-advanced-melanoma-exceeding-clinical-trial-results 2026-02-06T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/ixico-appoints-new-chief-commercial-officer-to-accelerate-neuroscience-imaging-business-growth 2026-02-06T01:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ixico-appoints-new-chief-commercial-officer-to-accelerate-neuroscience-imaging-business-growth 2026-02-06T01:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-genetic-testing-for-xeloda-and-5-fu-to-prevent-fatal-toxicities-in-dpd-deficient-patients 2026-02-06T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-genetic-testing-for-xeloda-and-5-fu-to-prevent-fatal-toxicities-in-dpd-deficient-patients 2026-02-06T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/abcuro-s-ulviprubart-misses-primary-endpoints-in-inclusion-body-myositis-trial-shows-promise-in-mild-to-moderate-patients 2026-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcuro-s-ulviprubart-misses-primary-endpoints-in-inclusion-body-myositis-trial-shows-promise-in-mild-to-moderate-patients 2026-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/urate-lowering-treatment-reduces-cardiovascular-risk-in-gout-patients-by-9 2026-02-05T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urate-lowering-treatment-reduces-cardiovascular-risk-in-gout-patients-by-9 2026-02-05T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/adarx-pharmaceuticals-appoints-donald-fong-as-chief-medical-officer-to-lead-rna-therapeutics-pipeline 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adarx-pharmaceuticals-appoints-donald-fong-as-chief-medical-officer-to-lead-rna-therapeutics-pipeline 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-heart-drug-dronedarone-shows-promise-as-novel-lymphoma-treatment-through-usp11-enzyme-targeting 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-heart-drug-dronedarone-shows-promise-as-novel-lymphoma-treatment-through-usp11-enzyme-targeting 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/menstrual-blood-hpv-testing-achieves-comparable-accuracy-to-clinician-sampling-in-large-chinese-study 2026-02-05T21:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menstrual-blood-hpv-testing-achieves-comparable-accuracy-to-clinician-sampling-in-large-chinese-study 2026-02-05T21:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-sweeping-policy-changes-to-accelerate-drug-approvals-and-transform-regulatory-landscape 2026-02-05T21:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-implements-sweeping-policy-changes-to-accelerate-drug-approvals-and-transform-regulatory-landscape 2026-02-05T21:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-cdmo-alphora-partners-with-uk-company-to-develop-revolutionary-adc-manufacturing-platform 2026-02-05T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eurofins-cdmo-alphora-partners-with-uk-company-to-develop-revolutionary-adc-manufacturing-platform 2026-02-05T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/infleqtion-advances-quantum-enabled-biomarker-discovery-for-precision-oncology-to-final-phase-of-wellcome-leap-challenge 2026-02-05T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infleqtion-advances-quantum-enabled-biomarker-discovery-for-precision-oncology-to-final-phase-of-wellcome-leap-challenge 2026-02-05T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vybrique-first-sildenafil-oral-film-for-erectile-dysfunction-treatment 2026-02-05T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-vybrique-first-sildenafil-oral-film-for-erectile-dysfunction-treatment 2026-02-05T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/sonorous-neurovascular-receives-fda-breakthrough-device-designation-for-bosstent-to-treat-pulsatile-tinnitus 2026-02-05T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonorous-neurovascular-receives-fda-breakthrough-device-designation-for-bosstent-to-treat-pulsatile-tinnitus 2026-02-05T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/crohn-s-disease-clinical-trials-show-promising-pipeline-with-novel-therapies-advancing-through-development 2026-02-05T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crohn-s-disease-clinical-trials-show-promising-pipeline-with-novel-therapies-advancing-through-development 2026-02-05T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-analysis-reveals-global-phenylketonuria-clinical-trials-landscape-and-strategic-opportunities 2026-02-05T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-market-analysis-reveals-global-phenylketonuria-clinical-trials-landscape-and-strategic-opportunities 2026-02-05T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/photonpharma-initiates-phase-1-trial-of-innocell-autologous-immunotherapy-for-recurrent-ovarian-cancer 2026-02-05T17:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/photonpharma-initiates-phase-1-trial-of-innocell-autologous-immunotherapy-for-recurrent-ovarian-cancer 2026-02-05T17:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-reduce-amputation-risk-and-cardiovascular-events-in-high-risk-diabetes-patients 2026-02-05T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-reduce-amputation-risk-and-cardiovascular-events-in-high-risk-diabetes-patients 2026-02-05T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/point-of-care-testing-for-hepatitis-b-dna-shows-high-accuracy-in-clinical-trial-expanding-access-to-diagnosis-and-treatment 2026-02-05T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/point-of-care-testing-for-hepatitis-b-dna-shows-high-accuracy-in-clinical-trial-expanding-access-to-diagnosis-and-treatment 2026-02-05T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-reports-positive-results-for-entyvio-biosimilar-in-pivotal-pharmacokinetic-study 2026-02-05T13:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-reports-positive-results-for-entyvio-biosimilar-in-pivotal-pharmacokinetic-study 2026-02-05T13:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/crest-2-trial-shows-carotid-revascularization-fails-to-improve-cognitive-function-in-asymptomatic-patients 2026-02-05T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crest-2-trial-shows-carotid-revascularization-fails-to-improve-cognitive-function-in-asymptomatic-patients 2026-02-05T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-streamlines-oncology-pipeline-discontinues-six-phase-1-cancer-programs 2026-02-05T09:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-streamlines-oncology-pipeline-discontinues-six-phase-1-cancer-programs 2026-02-05T09:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-liverpool-partners-with-bpgbio-to-advance-ai-driven-drug-discovery-platform 2026-02-05T09:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-liverpool-partners-with-bpgbio-to-advance-ai-driven-drug-discovery-platform 2026-02-05T09:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/orthocell-advances-us-commercial-strategy-following-fda-approval-for-nerve-repair-device 2026-02-05T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orthocell-advances-us-commercial-strategy-following-fda-approval-for-nerve-repair-device 2026-02-05T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-narrows-moderna-s-patent-defenses-in-8-2-billion-arbutus-lnp-technology-dispute 2026-02-05T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-court-narrows-moderna-s-patent-defenses-in-8-2-billion-arbutus-lnp-technology-dispute 2026-02-05T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-presents-promising-blood-brain-barrier-data-for-rare-disease-therapies-at-worldsymposium-2026 2026-02-05T05:02:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-presents-promising-blood-brain-barrier-data-for-rare-disease-therapies-at-worldsymposium-2026 2026-02-05T05:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-endovascular-completes-spirare-ii-trial-enrollment-for-vertex-pulmonary-embolectomy-system 2026-02-05T00:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-endovascular-completes-spirare-ii-trial-enrollment-for-vertex-pulmonary-embolectomy-system 2026-02-05T00:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/sovateltide-shows-92-success-rate-in-phase-iv-stroke-trial-demonstrating-significant-functional-recovery 2026-02-05T00:29:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sovateltide-shows-92-success-rate-in-phase-iv-stroke-trial-demonstrating-significant-functional-recovery 2026-02-05T00:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-ai-driven-analysis-confirms-vanoglipel-s-therapeutic-targets-for-mash-and-type-2-diabetes 2026-02-05T00:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-ai-driven-analysis-confirms-vanoglipel-s-therapeutic-targets-for-mash-and-type-2-diabetes 2026-02-05T00:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/fastest-trial-shows-mixed-results-for-factor-viia-in-acute-intracerebral-hemorrhage-signals-promise-in-early-treatment-subgroups 2026-02-05T00:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fastest-trial-shows-mixed-results-for-factor-viia-in-acute-intracerebral-hemorrhage-signals-promise-in-early-treatment-subgroups 2026-02-05T00:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-therapy-pipeline-expands-with-100-companies-developing-novel-cancer-treatments 2026-02-05T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytic-virus-therapy-pipeline-expands-with-100-companies-developing-novel-cancer-treatments 2026-02-05T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/coeptis-therapeutics-advances-cell-therapy-pipeline-while-pursuing-strategic-merger-with-cryptocurrency-mining-company 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coeptis-therapeutics-advances-cell-therapy-pipeline-while-pursuing-strategic-merger-with-cryptocurrency-mining-company 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-next-generation-cardiomems-hero-reader-receives-fda-approval-for-heart-failure-monitoring 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-next-generation-cardiomems-hero-reader-receives-fda-approval-for-heart-failure-monitoring 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-initiates-first-in-human-trial-of-ds3790-novel-cd37-targeted-adc-for-b-cell-lymphoma 2026-02-04T21:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-initiates-first-in-human-trial-of-ds3790-novel-cd37-targeted-adc-for-b-cell-lymphoma 2026-02-04T21:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-amphotericin-b-shows-comparable-efficacy-to-triazoles-in-invasive-aspergillosis-treatment 2026-02-04T21:01:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposomal-amphotericin-b-shows-comparable-efficacy-to-triazoles-in-invasive-aspergillosis-treatment 2026-02-04T21:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/qt-sense-secures-eur4m-to-advance-quantum-nanodiamond-platform-for-real-time-cellular-drug-discovery 2026-02-04T21:00:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qt-sense-secures-eur4m-to-advance-quantum-nanodiamond-platform-for-real-time-cellular-drug-discovery 2026-02-04T21:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/intra-arterial-alteplase-after-thrombectomy-shows-significant-improvement-in-stroke-recovery-outcomes 2026-02-04T20:58:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intra-arterial-alteplase-after-thrombectomy-shows-significant-improvement-in-stroke-recovery-outcomes 2026-02-04T20:58:24+00:00 hourly 0.9 https://trial.medpath.com/news/primegen-us-secures-1-5-billion-spac-merger-to-advance-triple-activated-stem-cell-platform-for-acute-liver-injury 2026-02-04T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primegen-us-secures-1-5-billion-spac-merger-to-advance-triple-activated-stem-cell-platform-for-acute-liver-injury 2026-02-04T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-study-shows-trx103-cell-therapy-accelerates-immune-recovery-in-mismatched-stem-cell-transplants 2026-02-04T17:28:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-study-shows-trx103-cell-therapy-accelerates-immune-recovery-in-mismatched-stem-cell-transplants 2026-02-04T17:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-launches-first-immunotherapy-trial-for-colorectal-cancer-in-sub-saharan-africa 2026-02-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-launches-first-immunotherapy-trial-for-colorectal-cancer-in-sub-saharan-africa 2026-02-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/third-arc-bio-raises-52-million-series-a-extension-to-advance-precision-immune-modulation-platform 2026-02-04T17:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-arc-bio-raises-52-million-series-a-extension-to-advance-precision-immune-modulation-platform 2026-02-04T17:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-appoints-eugene-kennedy-as-chief-medical-advisor-following-early-clinical-success-with-wee1-inhibitor 2026-02-04T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-appoints-eugene-kennedy-as-chief-medical-advisor-following-early-clinical-success-with-wee1-inhibitor 2026-02-04T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/axon-neuroscience-s-aadvac1-selected-for-two-major-nih-funded-platform-trials-in-alzheimer-s-and-psp 2026-02-04T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axon-neuroscience-s-aadvac1-selected-for-two-major-nih-funded-platform-trials-in-alzheimer-s-and-psp 2026-02-04T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-spatial-biology-analysis-reveals-new-insights-into-nsclc-immunotherapy-response 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-spatial-biology-analysis-reveals-new-insights-into-nsclc-immunotherapy-response 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-secures-five-year-commercial-supply-deal-with-bristol-myers-squibb-for-car-t-vector-manufacturing 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biomedica-secures-five-year-commercial-supply-deal-with-bristol-myers-squibb-for-car-t-vector-manufacturing 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-receives-fda-clearance-to-begin-phase-1-2-trial-of-aftx-201-gene-therapy-for-rare-heart-disease 2026-02-04T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-receives-fda-clearance-to-begin-phase-1-2-trial-of-aftx-201-gene-therapy-for-rare-heart-disease 2026-02-04T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-initiates-first-in-human-trial-of-novel-beta-catenin-condensate-modulator-dptx3186 2026-02-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dewpoint-therapeutics-initiates-first-in-human-trial-of-novel-beta-catenin-condensate-modulator-dptx3186 2026-02-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-faces-first-profit-decline-in-decade-as-key-drug-patents-expire 2026-02-04T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-faces-first-profit-decline-in-decade-as-key-drug-patents-expire 2026-02-04T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/aminex-therapeutics-initiates-phase-1b-2-trial-of-novel-polyamine-targeting-cancer-therapy-amxt-1501-plus-dfmo 2026-02-04T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aminex-therapeutics-initiates-phase-1b-2-trial-of-novel-polyamine-targeting-cancer-therapy-amxt-1501-plus-dfmo 2026-02-04T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/biodexa-secures-exclusive-license-for-novel-molecular-glue-mtx240-to-target-tki-resistant-gist 2026-02-04T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodexa-secures-exclusive-license-for-novel-molecular-glue-mtx240-to-target-tki-resistant-gist 2026-02-04T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/addex-therapeutics-publishes-breakthrough-data-on-mglu7-targeting-for-anxiety-and-ptsd-treatment 2026-02-04T17:24:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addex-therapeutics-publishes-breakthrough-data-on-mglu7-targeting-for-anxiety-and-ptsd-treatment 2026-02-04T17:24:14+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-and-shanghai-lishan-biopharmaceuticals-announce-exclusive-global-licensing-deal-for-bmc128-microbiome-cancer-therapy 2026-02-04T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-and-shanghai-lishan-biopharmaceuticals-announce-exclusive-global-licensing-deal-for-bmc128-microbiome-cancer-therapy 2026-02-04T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-to-present-final-phase-1b-results-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-02-04T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-to-present-final-phase-1b-results-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-02-04T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/hologic-s-aptima-hpv-assay-receives-fda-approval-for-primary-cervical-cancer-screening 2026-02-04T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hologic-s-aptima-hpv-assay-receives-fda-approval-for-primary-cervical-cancer-screening 2026-02-04T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2026-02-04T17:23:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2026-02-04T17:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-refuses-fda-request-to-withdraw-rare-disease-drug-tavneos-amid-data-integrity-concerns 2026-02-04T17:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-refuses-fda-request-to-withdraw-rare-disease-drug-tavneos-amid-data-integrity-concerns 2026-02-04T17:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/neomorph-begins-first-clinical-trial-of-molecular-glue-cancer-treatment-neo-811-for-kidney-cancer 2026-02-04T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neomorph-begins-first-clinical-trial-of-molecular-glue-cancer-treatment-neo-811-for-kidney-cancer 2026-02-04T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-implements-major-clinical-trial-reform-with-mandatory-ivd-assessment-starting-april-2026 2026-02-04T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-implements-major-clinical-trial-reform-with-mandatory-ivd-assessment-starting-april-2026 2026-02-04T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulatory-body-finds-sanofi-in-breach-over-unsubstantiated-rsv-therapy-claims-against-pfizer 2026-02-04T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulatory-body-finds-sanofi-in-breach-over-unsubstantiated-rsv-therapy-claims-against-pfizer 2026-02-04T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/forus-health-receives-cdsco-approval-for-ai-powered-diabetic-retinopathy-screening-tool-in-india 2026-02-04T13:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forus-health-receives-cdsco-approval-for-ai-powered-diabetic-retinopathy-screening-tool-in-india 2026-02-04T13:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/repotrectinib-demonstrates-durable-activity-in-ntrk-fusion-positive-solid-tumors-with-promising-outcomes-in-tki-pretreated-patients 2026-02-04T13:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repotrectinib-demonstrates-durable-activity-in-ntrk-fusion-positive-solid-tumors-with-promising-outcomes-in-tki-pretreated-patients 2026-02-04T13:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-to-showcase-accum-r-intracellular-delivery-platform-at-world-adc-europe-2026 2026-02-04T13:02:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-to-showcase-accum-r-intracellular-delivery-platform-at-world-adc-europe-2026 2026-02-04T13:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-appoints-dimitrios-chondros-as-chief-medical-officer-to-advance-t-cell-engager-platform 2026-02-04T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdr-life-appoints-dimitrios-chondros-as-chief-medical-officer-to-advance-t-cell-engager-platform 2026-02-04T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/major-cancer-research-coalition-launches-12-million-initiative-to-advance-early-detection-of-deadly-cancers 2026-02-04T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-cancer-research-coalition-launches-12-million-initiative-to-advance-early-detection-of-deadly-cancers 2026-02-04T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/cizzle-biotechnology-secures-canadian-patent-for-ciz1b-lung-cancer-biomarker-test 2026-02-04T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cizzle-biotechnology-secures-canadian-patent-for-ciz1b-lung-cancer-biomarker-test 2026-02-04T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-identifies-inkt-cell-depletion-as-key-mechanism-in-advanced-idiopathic-pulmonary-fibrosis 2026-02-04T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-identifies-inkt-cell-depletion-as-key-mechanism-in-advanced-idiopathic-pulmonary-fibrosis 2026-02-04T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-hiv-vaccine-candidate-induces-neutralizing-antibodies-in-nonhuman-primates 2026-02-04T01:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-hiv-vaccine-candidate-induces-neutralizing-antibodies-in-nonhuman-primates 2026-02-04T01:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/sanegenebio-secures-1-5-billion-rnai-licensing-deal-with-genentech 2026-02-04T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanegenebio-secures-1-5-billion-rnai-licensing-deal-with-genentech 2026-02-04T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/dash-bio-opens-24000-square-foot-glp-compliant-facility-to-accelerate-drug-development-bioanalysis 2026-02-04T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dash-bio-opens-24000-square-foot-glp-compliant-facility-to-accelerate-drug-development-bioanalysis 2026-02-04T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-secures-japanese-patent-for-autism-spectrum-disorder-therapeutic-mb-204 2026-02-04T01:02:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-secures-japanese-patent-for-autism-spectrum-disorder-therapeutic-mb-204 2026-02-04T01:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/quest-diagnostics-launches-noninvasive-blood-test-for-multiple-myeloma-residual-disease-monitoring 2026-02-04T01:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quest-diagnostics-launches-noninvasive-blood-test-for-multiple-myeloma-residual-disease-monitoring 2026-02-04T01:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-discontinues-cystic-fibrosis-gene-therapy-while-advancing-eur25-billion-r-d-investment-plan 2026-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-discontinues-cystic-fibrosis-gene-therapy-while-advancing-eur25-billion-r-d-investment-plan 2026-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-seattle-facility-receives-brazilian-gmp-certification-opening-access-to-40-billion-south-american-market 2026-02-03T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-seattle-facility-receives-brazilian-gmp-certification-opening-access-to-40-billion-south-american-market 2026-02-03T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-partners-with-samsung-biologics-to-strengthen-global-vaccine-manufacturing-for-future-pandemics 2026-02-03T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-partners-with-samsung-biologics-to-strengthen-global-vaccine-manufacturing-for-future-pandemics 2026-02-03T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-early-alert-for-impella-heart-pump-sensor-malfunction-linked-to-22-patient-injuries 2026-02-03T21:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-early-alert-for-impella-heart-pump-sensor-malfunction-linked-to-22-patient-injuries 2026-02-03T21:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/zipbio-and-meiragtx-partner-to-develop-ai-designed-gene-therapy-for-geographic-atrophy 2026-02-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipbio-and-meiragtx-partner-to-develop-ai-designed-gene-therapy-for-geographic-atrophy 2026-02-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/mapi-pharma-reports-promising-phase-ii-results-for-ga-depot-in-primary-progressive-multiple-sclerosis 2026-02-03T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mapi-pharma-reports-promising-phase-ii-results-for-ga-depot-in-primary-progressive-multiple-sclerosis 2026-02-03T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/neomorph-doses-first-patient-in-phase-1-2-trial-of-neo-811-molecular-glue-degrader-for-advanced-renal-cell-carcinoma 2026-02-03T21:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neomorph-doses-first-patient-in-phase-1-2-trial-of-neo-811-molecular-glue-degrader-for-advanced-renal-cell-carcinoma 2026-02-03T21:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/gentherm-submits-fda-510-k-application-for-first-of-kind-patient-warming-and-securement-system 2026-02-03T17:14:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gentherm-submits-fda-510-k-application-for-first-of-kind-patient-warming-and-securement-system 2026-02-03T17:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/tsc-life-receives-fda-clearance-for-pediatric-use-of-fluido-r-compact-blood-and-fluid-warming-system 2026-02-03T17:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tsc-life-receives-fda-clearance-for-pediatric-use-of-fluido-r-compact-blood-and-fluid-warming-system 2026-02-03T17:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-opens-phase-2-trial-combining-stenoparib-with-temozolomide-for-relapsed-small-cell-lung-cancer 2026-02-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allarity-therapeutics-opens-phase-2-trial-combining-stenoparib-with-temozolomide-for-relapsed-small-cell-lung-cancer 2026-02-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-appoints-thomas-civik-as-interim-ceo-to-advance-micvo-cancer-therapy-development 2026-02-03T17:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-appoints-thomas-civik-as-interim-ceo-to-advance-micvo-cancer-therapy-development 2026-02-03T17:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-slowing-age-related-macular-degeneration-progression 2026-02-03T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-slowing-age-related-macular-degeneration-progression 2026-02-03T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/merck-forecasts-2026-revenue-below-wall-street-estimates-as-patent-cliff-looms 2026-02-03T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-forecasts-2026-revenue-below-wall-street-estimates-as-patent-cliff-looms 2026-02-03T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/hookipa-pharma-sells-oncology-assets-including-hpv-and-kras-targeted-therapies-to-neotrail-therapeutics 2026-02-03T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hookipa-pharma-sells-oncology-assets-including-hpv-and-kras-targeted-therapies-to-neotrail-therapeutics 2026-02-03T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-approves-promega-s-msi-detection-kit-as-companion-diagnostic-for-keytruda 2026-02-03T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-approves-promega-s-msi-detection-kit-as-companion-diagnostic-for-keytruda 2026-02-03T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-licenses-novel-rsv-monoclonal-antibody-from-gates-medical-research-institute 2026-02-03T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-licenses-novel-rsv-monoclonal-antibody-from-gates-medical-research-institute 2026-02-03T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/valo-health-names-novo-nordisk-veteran-karin-conde-knape-as-chief-scientific-officer 2026-02-03T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valo-health-names-novo-nordisk-veteran-karin-conde-knape-as-chief-scientific-officer 2026-02-03T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-s-valiltramiprosate-shows-promising-biomarker-results-in-phase-3-alzheimer-s-trial 2026-02-03T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-s-valiltramiprosate-shows-promising-biomarker-results-in-phase-3-alzheimer-s-trial 2026-02-03T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-submits-upadacitinib-for-vitiligo-treatment-potentially-first-systemic-therapy-for-autoimmune-skin-disease 2026-02-03T17:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-submits-upadacitinib-for-vitiligo-treatment-potentially-first-systemic-therapy-for-autoimmune-skin-disease 2026-02-03T17:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-discontinues-claudin-6-adc-ds-9606-following-strategic-portfolio-review 2026-02-03T17:03:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-discontinues-claudin-6-adc-ds-9606-following-strategic-portfolio-review 2026-02-03T17:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/baysient-expands-precision-dosing-platform-to-17-inflammatory-disease-indications-with-idose-gen7-0-launch 2026-02-03T17:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baysient-expands-precision-dosing-platform-to-17-inflammatory-disease-indications-with-idose-gen7-0-launch 2026-02-03T17:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/preciseonco-consortium-secures-eur14-9-million-eu-grant-to-advance-ai-powered-precision-cancer-treatment 2026-02-03T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preciseonco-consortium-secures-eur14-9-million-eu-grant-to-advance-ai-powered-precision-cancer-treatment 2026-02-03T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/biosion-initiates-phase-1-trial-of-bsi-082-anti-sirpa-antibody-for-advanced-solid-tumors 2026-02-03T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosion-initiates-phase-1-trial-of-bsi-082-anti-sirpa-antibody-for-advanced-solid-tumors 2026-02-03T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/expres2ion-biotech-reports-promising-immune-response-data-from-her2-targeting-cancer-vaccine-phase-i-trial 2026-02-03T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expres2ion-biotech-reports-promising-immune-response-data-from-her2-targeting-cancer-vaccine-phase-i-trial 2026-02-03T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/hemostod-secures-chf-2-million-innosuisse-grant-to-advance-universal-donor-free-platelet-technology 2026-02-03T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostod-secures-chf-2-million-innosuisse-grant-to-advance-universal-donor-free-platelet-technology 2026-02-03T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-metastasis-directed-therapy-benefits-for-oligometastatic-prostate-cancer 2026-02-03T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-metastasis-directed-therapy-benefits-for-oligometastatic-prostate-cancer 2026-02-03T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-plans-1500-member-scientific-cadre-to-accelerate-drug-approvals-and-meet-global-standards 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-plans-1500-member-scientific-cadre-to-accelerate-drug-approvals-and-meet-global-standards 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-astrazeneca-s-subcutaneous-lupus-drug-saphnelo-despite-eu-approval 2026-02-03T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-astrazeneca-s-subcutaneous-lupus-drug-saphnelo-despite-eu-approval 2026-02-03T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharming-advances-rare-disease-pipeline-with-napazimone-for-mitochondrial-disease-and-leniolisib-expansion 2026-02-03T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharming-advances-rare-disease-pipeline-with-napazimone-for-mitochondrial-disease-and-leniolisib-expansion 2026-02-03T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/large-swedish-study-finds-no-link-between-covid-19-vaccines-and-reduced-fertility 2026-02-03T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-swedish-study-finds-no-link-between-covid-19-vaccines-and-reduced-fertility 2026-02-03T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/persica-pharmaceuticals-pp353-shows-promising-results-for-chronic-low-back-pain-in-phase-1b-trial-published-in-the-lancet 2026-02-03T09:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persica-pharmaceuticals-pp353-shows-promising-results-for-chronic-low-back-pain-in-phase-1b-trial-published-in-the-lancet 2026-02-03T09:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/nmd-pharma-s-ignaseclant-shows-promise-in-phase-2a-trial-for-charcot-marie-tooth-disease 2026-02-03T09:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmd-pharma-s-ignaseclant-shows-promise-in-phase-2a-trial-for-charcot-marie-tooth-disease 2026-02-03T09:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/vtv-therapeutics-expands-global-partnership-with-newsoara-for-pde4-inhibitor-hpp737-in-135-million-deal 2026-02-03T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vtv-therapeutics-expands-global-partnership-with-newsoara-for-pde4-inhibitor-hpp737-in-135-million-deal 2026-02-03T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-reduce-gout-medication-burden-in-patients-with-type-2-diabetes 2026-02-03T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-reduce-gout-medication-burden-in-patients-with-type-2-diabetes 2026-02-03T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/salspera-files-ipo-to-fund-phase-3-trial-of-saltikva-bacterial-immunotherapy-for-pancreatic-cancer 2026-02-03T01:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salspera-files-ipo-to-fund-phase-3-trial-of-saltikva-bacterial-immunotherapy-for-pancreatic-cancer 2026-02-03T01:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-files-ind-application-for-magsense-targeted-imaging-agent-in-her2-positive-breast-cancer 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagion-biosystems-files-ind-application-for-magsense-targeted-imaging-agent-in-her2-positive-breast-cancer 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-supported-mammography-screening-demonstrates-superior-cancer-detection-in-large-swedish-trial 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-supported-mammography-screening-demonstrates-superior-cancer-detection-in-large-swedish-trial 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-completes-enrollment-in-phase-2-lotus-trial-for-hidradenitis-suppurativa-treatment 2026-02-03T01:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalo-therapeutics-completes-enrollment-in-phase-2-lotus-trial-for-hidradenitis-suppurativa-treatment 2026-02-03T01:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-proposes-ministerial-reliance-order-to-accelerate-drug-approvals-through-foreign-regulatory-collaboration 2026-02-03T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-proposes-ministerial-reliance-order-to-accelerate-drug-approvals-through-foreign-regulatory-collaboration 2026-02-03T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-secures-nmpa-approval-for-advanced-ophthalmic-microscopes-in-china 2026-02-03T01:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-secures-nmpa-approval-for-advanced-ophthalmic-microscopes-in-china 2026-02-03T01:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/novel-stroke-rehabilitation-approach-targeting-good-arm-shows-significant-motor-improvements-in-phase-ii-trial 2026-02-03T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-stroke-rehabilitation-approach-targeting-good-arm-shows-significant-motor-improvements-in-phase-ii-trial 2026-02-03T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-approves-reimbursement-for-fruzaqla-in-metastatic-colorectal-cancer-treatment 2026-02-02T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-approves-reimbursement-for-fruzaqla-in-metastatic-colorectal-cancer-treatment 2026-02-02T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/australia-launches-world-first-personalized-mrna-vaccine-trial-for-pediatric-brain-cancer 2026-02-02T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-launches-world-first-personalized-mrna-vaccine-trial-for-pediatric-brain-cancer 2026-02-02T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-launches-tablet-in-capsule-technology-for-enhanced-drug-delivery 2026-02-02T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-launches-tablet-in-capsule-technology-for-enhanced-drug-delivery 2026-02-02T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-names-susan-keefe-as-cfo-to-advance-somatic-genomics-platform 2026-02-02T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-therapeutics-names-susan-keefe-as-cfo-to-advance-somatic-genomics-platform 2026-02-02T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/sanegenebio-secures-1-7-billion-rnai-licensing-deal-with-genentech 2026-02-02T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanegenebio-secures-1-7-billion-rnai-licensing-deal-with-genentech 2026-02-02T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/ensem-therapeutics-expands-etx-636-trial-to-china-targeting-pi3ka-mutations-in-cancer 2026-02-02T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensem-therapeutics-expands-etx-636-trial-to-china-targeting-pi3ka-mutations-in-cancer 2026-02-02T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-secures-u-s-patent-for-cannabinoid-enhanced-antimicrobial-platform-targeting-mrsa-and-antibiotic-resistance 2026-02-02T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-secures-u-s-patent-for-cannabinoid-enhanced-antimicrobial-platform-targeting-mrsa-and-antibiotic-resistance 2026-02-02T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-therapeutics-launches-investigator-initiated-study-for-once-daily-cystinosis-treatment 2026-02-02T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thiogenesis-therapeutics-launches-investigator-initiated-study-for-once-daily-cystinosis-treatment 2026-02-02T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/teva-canada-partners-with-novartis-to-commercialize-multiple-sclerosis-treatment-mayzent 2026-02-02T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-canada-partners-with-novartis-to-commercialize-multiple-sclerosis-treatment-mayzent 2026-02-02T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-canada-launches-first-ophthalmology-biosimilar-enzeevu-for-retinal-diseases 2026-02-02T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-canada-launches-first-ophthalmology-biosimilar-enzeevu-for-retinal-diseases 2026-02-02T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/acurx-pharmaceuticals-secures-new-patent-for-dna-polymerase-iiic-inhibitors-targeting-antibiotic-resistant-bacteria 2026-02-02T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurx-pharmaceuticals-secures-new-patent-for-dna-polymerase-iiic-inhibitors-targeting-antibiotic-resistant-bacteria 2026-02-02T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/oxybutynin-demonstrates-significant-efficacy-in-reducing-hot-flashes-for-prostate-cancer-patients-on-hormone-therapy 2026-02-02T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxybutynin-demonstrates-significant-efficacy-in-reducing-hot-flashes-for-prostate-cancer-patients-on-hormone-therapy 2026-02-02T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/crystalys-therapeutics-expands-phase-3-ruby-study-to-europe-for-gout-treatment-dotinurad 2026-02-02T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crystalys-therapeutics-expands-phase-3-ruby-study-to-europe-for-gout-treatment-dotinurad 2026-02-02T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/erleada-shows-51-reduction-in-death-risk-versus-darolutamide-in-real-world-prostate-cancer-study 2026-02-02T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erleada-shows-51-reduction-in-death-risk-versus-darolutamide-in-real-world-prostate-cancer-study 2026-02-02T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/en-carta-diagnostics-receives-fda-breakthrough-device-designation-for-revolutionary-lyme-disease-test 2026-02-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/en-carta-diagnostics-receives-fda-breakthrough-device-designation-for-revolutionary-lyme-disease-test 2026-02-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-partners-with-university-of-minnesota-to-advance-carbohydrate-based-therapeutics-through-nmr-research 2026-02-02T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-partners-with-university-of-minnesota-to-advance-carbohydrate-based-therapeutics-through-nmr-research 2026-02-02T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/jumo-health-launches-prism-system-to-address-clinical-trial-patient-readiness-and-retention-challenges 2026-02-02T17:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jumo-health-launches-prism-system-to-address-clinical-trial-patient-readiness-and-retention-challenges 2026-02-02T17:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-advances-toward-phase-2a-trial-for-first-in-class-concussion-treatment-onp-002 2026-02-02T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-advances-toward-phase-2a-trial-for-first-in-class-concussion-treatment-onp-002 2026-02-02T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-returns-rna-editing-drug-wve-006-to-wave-life-sciences-following-disappointing-aatd-trial-data 2026-02-02T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-returns-rna-editing-drug-wve-006-to-wave-life-sciences-following-disappointing-aatd-trial-data 2026-02-02T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/biorce-raises-52-5-million-series-a-to-transform-clinical-trials-with-ai-platform 2026-02-02T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorce-raises-52-5-million-series-a-to-transform-clinical-trials-with-ai-platform 2026-02-02T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/southern-research-partners-with-pathogenus-to-expand-global-reach-in-respiratory-disease-and-cancer-research 2026-02-02T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/southern-research-partners-with-pathogenus-to-expand-global-reach-in-respiratory-disease-and-cancer-research 2026-02-02T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-partners-with-sandoz-to-expand-biosimilar-access-across-canada-australia-and-new-zealand 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-partners-with-sandoz-to-expand-biosimilar-access-across-canada-australia-and-new-zealand 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/gameto-licenses-harvard-meiosis-technology-to-advance-human-ovary-in-a-dish-platform-for-women-s-health 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gameto-licenses-harvard-meiosis-technology-to-advance-human-ovary-in-a-dish-platform-for-women-s-health 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/kahimmune-therapeutics-secures-exclusive-license-for-dark-genome-cancer-vaccine-platform 2026-02-02T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kahimmune-therapeutics-secures-exclusive-license-for-dark-genome-cancer-vaccine-platform 2026-02-02T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-supreme-court-to-determine-competition-commission-s-authority-over-patent-related-antitrust-cases 2026-02-02T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-supreme-court-to-determine-competition-commission-s-authority-over-patent-related-antitrust-cases 2026-02-02T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-vision-acquires-mdco-technology-s-ophthalmic-device-business-to-create-integrated-drug-device-platform 2026-02-02T05:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-vision-acquires-mdco-technology-s-ophthalmic-device-business-to-create-integrated-drug-device-platform 2026-02-02T05:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/nice-withdraws-car-t-therapy-tecartus-from-nhs-despite-patient-advocacy-appeals 2026-02-02T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-withdraws-car-t-therapy-tecartus-from-nhs-despite-patient-advocacy-appeals 2026-02-02T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/international-consortium-develops-revolutionary-platform-to-predict-human-antibody-drug-responses 2026-02-02T05:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-consortium-develops-revolutionary-platform-to-predict-human-antibody-drug-responses 2026-02-02T05:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/texas-cardiac-arrhythmia-institute-performs-first-u-s-implantation-of-fda-approved-miniaturized-defibrillation-lead 2026-02-02T05:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-cardiac-arrhythmia-institute-performs-first-u-s-implantation-of-fda-approved-miniaturized-defibrillation-lead 2026-02-02T05:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-insti-hiv-treatment-shows-promise-in-phase-3-trial-amid-rising-resistance-concerns 2026-02-02T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-insti-hiv-treatment-shows-promise-in-phase-3-trial-amid-rising-resistance-concerns 2026-02-02T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/reata-pharmaceuticals-shifts-focus-to-omaveloxolone-commercialization-following-friedreich-s-ataxia-approval 2026-02-02T01:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reata-pharmaceuticals-shifts-focus-to-omaveloxolone-commercialization-following-friedreich-s-ataxia-approval 2026-02-02T01:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/scot-trial-confirms-3-month-adjuvant-chemotherapy-noninferior-to-6-month-standard-for-colorectal-cancer 2026-02-02T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scot-trial-confirms-3-month-adjuvant-chemotherapy-noninferior-to-6-month-standard-for-colorectal-cancer 2026-02-02T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-hansoh-pharma-advance-next-generation-her2-targeted-adc-gsk5764227-in-early-clinical-trials 2026-02-01T21:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-hansoh-pharma-advance-next-generation-her2-targeted-adc-gsk5764227-in-early-clinical-trials 2026-02-01T21:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/india-announces-rs-10000-crore-biopharma-shakti-initiative-and-cdsco-regulatory-overhaul-in-union-budget-2026 2026-02-01T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-announces-rs-10000-crore-biopharma-shakti-initiative-and-cdsco-regulatory-overhaul-in-union-budget-2026 2026-02-01T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-rs-10000-crore-biopharma-shakti-initiative-and-exempts-17-cancer-drugs-from-import-duties 2026-02-01T09:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-rs-10000-crore-biopharma-shakti-initiative-and-exempts-17-cancer-drugs-from-import-duties 2026-02-01T09:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/tenacia-biopharmaceuticals-partners-with-golden-age-health-to-launch-first-cdkl5-deficiency-disorder-treatment-in-china 2026-02-01T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenacia-biopharmaceuticals-partners-with-golden-age-health-to-launch-first-cdkl5-deficiency-disorder-treatment-in-china 2026-02-01T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-bans-stem-cell-therapy-for-autism-outside-clinical-trials-declares-practice-medical-malpractice 2026-02-01T09:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-bans-stem-cell-therapy-for-autism-outside-clinical-trials-declares-practice-medical-malpractice 2026-02-01T09:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/olema-pharmaceuticals-faces-leadership-transition-as-pivotal-breast-cancer-trial-data-approaches 2026-02-01T09:02:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-pharmaceuticals-faces-leadership-transition-as-pivotal-breast-cancer-trial-data-approaches 2026-02-01T09:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/trace-biosciences-receives-fda-ind-clearance-for-first-in-class-nerve-specific-imaging-agent-lgw16-03 2026-02-01T09:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trace-biosciences-receives-fda-ind-clearance-for-first-in-class-nerve-specific-imaging-agent-lgw16-03 2026-02-01T09:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/cbd-shows-promise-in-reducing-fetal-alcohol-spectrum-disorder-effects-through-endocannabinoid-system-modulation 2026-02-01T00:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbd-shows-promise-in-reducing-fetal-alcohol-spectrum-disorder-effects-through-endocannabinoid-system-modulation 2026-02-01T00:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-completes-long-term-real-world-study-of-nucala-in-rare-eosinophilic-disease-egpa 2026-02-01T00:11:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-completes-long-term-real-world-study-of-nucala-in-rare-eosinophilic-disease-egpa 2026-02-01T00:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/ardena-completes-divestment-of-swedish-api-manufacturing-site-to-nanologica 2026-01-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ardena-completes-divestment-of-swedish-api-manufacturing-site-to-nanologica 2026-01-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-lawmakers-propose-patent-break-for-eli-lilly-s-mounjaro-as-ozempic-patent-expires 2026-01-31T13:03:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-lawmakers-propose-patent-break-for-eli-lilly-s-mounjaro-as-ozempic-patent-expires 2026-01-31T13:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/nasal-spray-h5n1-vaccine-shows-near-complete-protection-in-early-animal-studies 2026-01-31T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasal-spray-h5n1-vaccine-shows-near-complete-protection-in-early-animal-studies 2026-01-31T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-secures-fda-approval-for-generic-lacosamide-oral-solution-for-epilepsy-treatment 2026-01-31T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indoco-remedies-secures-fda-approval-for-generic-lacosamide-oral-solution-for-epilepsy-treatment 2026-01-31T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/vivosim-labs-expands-human-based-toxicology-services-to-asia-pacific-through-strategic-distribution-partnerships 2026-01-31T01:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivosim-labs-expands-human-based-toxicology-services-to-asia-pacific-through-strategic-distribution-partnerships 2026-01-31T01:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-patent-litigation-wave-intensifies-in-q4-2025-as-generic-manufacturers-challenge-key-drug-patents 2026-01-31T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-patent-litigation-wave-intensifies-in-q4-2025-as-generic-manufacturers-challenge-key-drug-patents 2026-01-31T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-builds-1-5-billion-pre-launch-inventory-for-oral-glp-1-obesity-drug-ahead-of-fda-decision 2026-01-30T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-builds-1-5-billion-pre-launch-inventory-for-oral-glp-1-obesity-drug-ahead-of-fda-decision 2026-01-30T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-completes-350-million-acquisition-of-somalogic-to-expand-proteomics-leadership 2026-01-30T21:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-completes-350-million-acquisition-of-somalogic-to-expand-proteomics-leadership 2026-01-30T21:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-regains-control-of-rocatinlimab-development-following-amgen-partnership-termination 2026-01-30T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyowa-kirin-regains-control-of-rocatinlimab-development-following-amgen-partnership-termination 2026-01-30T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-cmo-jacqueline-miller-steps-down-as-company-seeks-to-expand-beyond-covid-vaccines 2026-01-30T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-cmo-jacqueline-miller-steps-down-as-company-seeks-to-expand-beyond-covid-vaccines 2026-01-30T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-positive-phase-iii-results-for-fabhalta-in-rare-kidney-disease-c3-glomerulopathy 2026-01-30T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-reports-positive-phase-iii-results-for-fabhalta-in-rare-kidney-disease-c3-glomerulopathy 2026-01-30T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-partners-with-origami-therapeutics-on-protein-degrader-program-for-rare-neurodegenerative-diseases 2026-01-30T21:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-partners-with-origami-therapeutics-on-protein-degrader-program-for-rare-neurodegenerative-diseases 2026-01-30T21:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/kos-biotechnology-partners-makes-inaugural-investment-in-epikast-s-technology-enabled-pharma-services-platform 2026-01-30T21:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kos-biotechnology-partners-makes-inaugural-investment-in-epikast-s-technology-enabled-pharma-services-platform 2026-01-30T21:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-restructures-r-d-leadership-as-executive-vp-berman-departs 2026-01-30T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-restructures-r-d-leadership-as-executive-vp-berman-departs 2026-01-30T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-unveils-first-in-class-nuclear-pd-l1-degrader-ndl2-targeting-immunotherapy-resistance 2026-01-30T17:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-unveils-first-in-class-nuclear-pd-l1-degrader-ndl2-targeting-immunotherapy-resistance 2026-01-30T17:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-16-million-pipe-investment-to-advance-cns-cancer-therapies 2026-01-30T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-secures-16-million-pipe-investment-to-advance-cns-cancer-therapies 2026-01-30T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-needle-free-nasal-epinephrine-spray-for-pediatric-anaphylaxis 2026-01-30T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-of-needle-free-nasal-epinephrine-spray-for-pediatric-anaphylaxis 2026-01-30T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-data-integrity-review-of-amgen-s-tavneos-following-concerns-over-pivotal-advocate-study 2026-01-30T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-initiates-data-integrity-review-of-amgen-s-tavneos-following-concerns-over-pivotal-advocate-study 2026-01-30T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-emerges-as-first-proven-intervention-to-prevent-long-covid-in-adults 2026-01-30T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-emerges-as-first-proven-intervention-to-prevent-long-covid-in-adults 2026-01-30T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/brain-swelling-from-alzheimer-s-drugs-may-signal-treatment-success-new-research-suggests 2026-01-30T13:03:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-swelling-from-alzheimer-s-drugs-may-signal-treatment-success-new-research-suggests 2026-01-30T13:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/poxel-emerges-from-judicial-reorganization-with-court-approved-recovery-plan 2026-01-30T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poxel-emerges-from-judicial-reorganization-with-court-approved-recovery-plan 2026-01-30T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-frostbite-drug-iloprost-shows-zero-amputation-rate-in-clinical-use-at-ohio-hospitals 2026-01-30T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-frostbite-drug-iloprost-shows-zero-amputation-rate-in-clinical-use-at-ohio-hospitals 2026-01-30T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/sciwind-biosciences-receives-chinese-approval-for-glp-1-diabetes-drug-xianyida 2026-01-30T09:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sciwind-biosciences-receives-chinese-approval-for-glp-1-diabetes-drug-xianyida 2026-01-30T09:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-advances-hmbd-002-to-phase-ii-following-positive-safety-data-in-cancer-trial 2026-01-30T05:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-advances-hmbd-002-to-phase-ii-following-positive-safety-data-in-cancer-trial 2026-01-30T05:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-bioelectronic-patch-enables-precision-drug-delivery-to-complex-organs 2026-01-30T05:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-bioelectronic-patch-enables-precision-drug-delivery-to-complex-organs 2026-01-30T05:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-hiring-rebounds-as-companies-embrace-remote-work-and-ai-skills 2026-01-30T03:02:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-hiring-rebounds-as-companies-embrace-remote-work-and-ai-skills 2026-01-30T03:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-raises-94-6-million-to-advance-drug-pipeline-in-neuropathic-pain-and-hypertrophic-cardiomyopathy 2026-01-30T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-raises-94-6-million-to-advance-drug-pipeline-in-neuropathic-pain-and-hypertrophic-cardiomyopathy 2026-01-30T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/metp-pharma-s-nose-to-brain-technology-achieves-superior-peptide-delivery-compared-to-blood-brain-barrier-shuttles 2026-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metp-pharma-s-nose-to-brain-technology-achieves-superior-peptide-delivery-compared-to-blood-brain-barrier-shuttles 2026-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-m-a-surge-expected-as-200-billion-patent-cliff-drives-big-pharma-acquisition-strategy 2026-01-30T01:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-m-a-surge-expected-as-200-billion-patent-cliff-drives-big-pharma-acquisition-strategy 2026-01-30T01:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-combination-therapy-shows-remarkable-success-in-metastatic-esophageal-cancer-patient 2026-01-30T01:01:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tucatinib-combination-therapy-shows-remarkable-success-in-metastatic-esophageal-cancer-patient 2026-01-30T01:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bite-immunotherapy-reduces-arterial-plaque-in-preclinical-atherosclerosis-study 2026-01-29T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bite-immunotherapy-reduces-arterial-plaque-in-preclinical-atherosclerosis-study 2026-01-29T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-bead-free-microfluidics-method-to-streamline-car-t-cell-manufacturing 2026-01-29T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-bead-free-microfluidics-method-to-streamline-car-t-cell-manufacturing 2026-01-29T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/geneva-team-wins-pfizer-prize-for-personalized-cancer-vaccine-mvx-onco-1-showing-clinical-benefit-in-advanced-tumors 2026-01-29T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneva-team-wins-pfizer-prize-for-personalized-cancer-vaccine-mvx-onco-1-showing-clinical-benefit-in-advanced-tumors 2026-01-29T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-repertoire-immune-medicines-in-1-93-billion-autoimmune-disease-deal 2026-01-29T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-partners-with-repertoire-immune-medicines-in-1-93-billion-autoimmune-disease-deal 2026-01-29T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/nucleic-acid-therapeutics-contract-manufacturing-market-surges-to-33-84-billion-by-2033 2026-01-29T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucleic-acid-therapeutics-contract-manufacturing-market-surges-to-33-84-billion-by-2033 2026-01-29T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/breakthru-medicine-emerges-from-stealth-with-60m-series-a-to-develop-novel-cancer-therapeutics 2026-01-29T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthru-medicine-emerges-from-stealth-with-60m-series-a-to-develop-novel-cancer-therapeutics 2026-01-29T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/pulmonary-arterial-hypertension-pipeline-expands-with-55-therapies-as-merck-s-winrevair-shows-76-mortality-risk-reduction 2026-01-29T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmonary-arterial-hypertension-pipeline-expands-with-55-therapies-as-merck-s-winrevair-shows-76-mortality-risk-reduction 2026-01-29T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/micurx-receives-fda-clearance-to-advance-mrx-5-into-phase-2a-trial-for-mycobacterium-abscessus-pulmonary-disease 2026-01-29T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/micurx-receives-fda-clearance-to-advance-mrx-5-into-phase-2a-trial-for-mycobacterium-abscessus-pulmonary-disease 2026-01-29T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-receives-milestone-payment-from-takeda-as-atac-based-adc-enters-phase-i-ii-trial 2026-01-29T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-receives-milestone-payment-from-takeda-as-atac-based-adc-enters-phase-i-ii-trial 2026-01-29T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-advances-multi-platform-pipeline-with-prolectin-m-under-fda-ind-and-oxygen-transport-programs 2026-01-29T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-advances-multi-platform-pipeline-with-prolectin-m-under-fda-ind-and-oxygen-transport-programs 2026-01-29T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-s-ai-designed-gipr-antagonist-ism0676-achieves-31-3-weight-loss-in-preclinical-studies 2026-01-29T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-s-ai-designed-gipr-antagonist-ism0676-achieves-31-3-weight-loss-in-preclinical-studies 2026-01-29T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-jcog0603-trial-results-show-no-overall-survival-benefit-from-adjuvant-mfolfox6-after-liver-resection-for-colorectal-metastases 2026-01-29T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-jcog0603-trial-results-show-no-overall-survival-benefit-from-adjuvant-mfolfox6-after-liver-resection-for-colorectal-metastases 2026-01-29T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/dod-awards-genomind-contract-to-implement-pharmacogenomics-testing-for-active-duty-service-members 2026-01-29T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-awards-genomind-contract-to-implement-pharmacogenomics-testing-for-active-duty-service-members 2026-01-29T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/panakeia-s-ai-software-achieves-landmark-validation-for-rapid-colorectal-cancer-molecular-profiling 2026-01-29T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panakeia-s-ai-software-achieves-landmark-validation-for-rapid-colorectal-cancer-molecular-profiling 2026-01-29T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-meta-analysis-finds-no-significant-vision-risk-from-glp-1-receptor-agonists-in-80000-patients 2026-01-29T17:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-meta-analysis-finds-no-significant-vision-risk-from-glp-1-receptor-agonists-in-80000-patients 2026-01-29T17:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-reports-second-partial-response-for-wee1-inhibitor-apr-1051-in-phase-1-endometrial-cancer-trial 2026-01-29T13:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-reports-second-partial-response-for-wee1-inhibitor-apr-1051-in-phase-1-endometrial-cancer-trial 2026-01-29T13:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-pritelivir-demonstrates-superior-efficacy-in-phase-3-trial-for-drug-resistant-hsv-infections 2026-01-29T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aicuris-pritelivir-demonstrates-superior-efficacy-in-phase-3-trial-for-drug-resistant-hsv-infections 2026-01-29T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/pre-surgical-pembrolizumab-achieves-71-complete-response-rate-in-desmoplastic-melanoma-trial 2026-01-29T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-surgical-pembrolizumab-achieves-71-complete-response-rate-in-desmoplastic-melanoma-trial 2026-01-29T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/darolutamide-receives-third-approval-in-china-for-metastatic-hormone-sensitive-prostate-cancer 2026-01-29T13:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/darolutamide-receives-third-approval-in-china-for-metastatic-hormone-sensitive-prostate-cancer 2026-01-29T13:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-seysara-for-moderate-to-severe-acne-treatment-in-patients-9-years-and-older 2026-01-29T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-seysara-for-moderate-to-severe-acne-treatment-in-patients-9-years-and-older 2026-01-29T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-initiates-phase-ii-trial-of-inna-051-nasal-spray-for-viral-respiratory-infection-prevention 2026-01-29T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ena-respiratory-initiates-phase-ii-trial-of-inna-051-nasal-spray-for-viral-respiratory-infection-prevention 2026-01-29T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncoinvent-expands-phase-2-trial-sites-for-radspherin-radiopharmaceutical-in-ovarian-cancer 2026-01-29T13:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoinvent-expands-phase-2-trial-sites-for-radspherin-radiopharmaceutical-in-ovarian-cancer 2026-01-29T13:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-qualifies-moleculightdx-as-medical-device-development-tool-for-wound-care-innovation 2026-01-29T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-qualifies-moleculightdx-as-medical-device-development-tool-for-wound-care-innovation 2026-01-29T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-strengthens-board-with-beigene-s-former-cmo-as-oncomimics-platform-shows-promise-in-cancer-trials 2026-01-29T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-strengthens-board-with-beigene-s-former-cmo-as-oncomimics-platform-shows-promise-in-cancer-trials 2026-01-29T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/eyestem-receives-cdsco-approval-for-phase-2-trial-of-stem-cell-therapy-for-dry-amd 2026-01-29T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyestem-receives-cdsco-approval-for-phase-2-trial-of-stem-cell-therapy-for-dry-amd 2026-01-29T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-receives-fda-ind-clearance-for-ser-252-parkinson-s-disease-therapy 2026-01-29T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-receives-fda-ind-clearance-for-ser-252-parkinson-s-disease-therapy 2026-01-29T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/qurebio-s-q-1802-bispecific-antibody-shows-70-response-rate-in-advanced-gastric-cancer-phase-ii-trial 2026-01-29T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qurebio-s-q-1802-bispecific-antibody-shows-70-response-rate-in-advanced-gastric-cancer-phase-ii-trial 2026-01-29T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/avobis-bio-reports-positive-expanded-stomp2-trial-results-for-crohn-s-perianal-fistula-cell-therapy 2026-01-29T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avobis-bio-reports-positive-expanded-stomp2-trial-results-for-crohn-s-perianal-fistula-cell-therapy 2026-01-29T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-receives-michael-j-fox-foundation-grant-to-develop-trpml1-biomarkers-for-parkinson-s-disease 2026-01-29T05:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexorg-receives-michael-j-fox-foundation-grant-to-develop-trpml1-biomarkers-for-parkinson-s-disease 2026-01-29T05:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabtech-and-sai-life-sciences-form-strategic-partnership-to-expand-eyra-immunology-platform-access-in-us-market 2026-01-29T05:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabtech-and-sai-life-sciences-form-strategic-partnership-to-expand-eyra-immunology-platform-access-in-us-market 2026-01-29T05:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-launches-first-in-class-universal-coronavirus-vaccine-trial-targeting-entire-sarbecovirus-family 2026-01-29T05:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-launches-first-in-class-universal-coronavirus-vaccine-trial-targeting-entire-sarbecovirus-family 2026-01-29T05:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-biopharmaceuticals-advances-osteoarthritis-program-with-peer-reviewed-validation-of-injectable-pps 2026-01-29T05:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-biopharmaceuticals-advances-osteoarthritis-program-with-peer-reviewed-validation-of-injectable-pps 2026-01-29T05:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia-treatment 2026-01-29T05:01:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia-treatment 2026-01-29T05:01:52+00:00 hourly 0.9